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When a blood vessel is damaged it is important that bleeding stops rapidly. In healthy 
individuals the coagulation system is triggered immediately. A clot is formed to stop the 
bleeding and to enable vessel repair. After the vessel wall integrity is re-established the clot 
is dissolved by the fibrinolytic system. 
Venous thrombosis is a result of a disturbance of the balance of the pro- and anticoagulant 
system or the pro- and antifibrinolytic system towards the prothrombotic side. This 
disturbance can be caused by acquired and genetic risk factors. In the 19th century Virchow 
proposed a theory in which he considers three causes of thrombosis, i.e. alterations of the 
blood flow (stasis), vascular endothelial injury, or alterations in the constitution of the 
blood. These three conditions are known as Virchow’s triad, which is still valid today1.
Venous thrombosis is an occlusion by a blood clot of one or more of the veins; this occurs mostly 
in the leg but may affect every vein in the body. The occlusion of a vein in the leg may cause 
swelling, redness and pain of the affected limb. When part of a clot dislodges it can travel up 
through the lower caval vein through the heart to the lungs were occlusion of pulmonary vessels 
leads to symptoms of pulmonary embolism. Venous thrombosis occurs in 1-2 per 1000 persons 
per year2. The incidence increases with age from 1 per 10 000 in the young up to 1 per 100 in the 
elderly3. About one third of the thrombotic clots form emboli that cause pulmonary emboli2,3. 
Complications of venous thrombosis include pulmonary hypertension (incidence 3% per year)4, 
the post thrombotic syndrome (cumulative incidence 25-50% after 1-2 years)5, and bleeding due 
to treatment with anticoagulants (incidence of major bleeding 1.4-2.7% per year)6. 
Venous thrombosis is a potentially lethal disease due to pulmonary embolism. Pulmonary 
emboli are lethal in about 20% of the cases3. Mortality remains elevated for several years 
after the thrombotic event, mainly for patients with a first idiopathic venous thrombosis 
or patients with venous thrombosis due to malignancy3. Twelve percent of patients with 
venous thrombosis without malignancy die within one year after the thrombotic event. This 
implies that venous thrombosis has a major impact on mortality3,7.  
Risk factors for a first venous thrombosis
Venous thrombosis is a multicausal disease. Many genetic and acquired risk factors have 
been described that increase the risk of venous thrombosis. Furthermore, many of these 
risk factors interact with each other, resulting in a higher risk of a thrombotic event than 
expected based on the separate effects of these factors8,9. Most genetic risk factors known 
are variations in genes that are involved in the coagulation system, i.e., mutations in protein 
C and S genes, factor V Leiden (FVL, rs6025) and the prothrombin G20210A mutation 
(rs1799963), FGG 10034 and Von Willebrand Factor (VWF)10,11. In a clinical setting 





although the clinical utility is disputed. The FVL mutation is prevalent with about 5% of the 
Caucasian population carrying this mutation. FVL increases the risk of venous thrombosis 
5-fold and interacts synergistically with several acquired risk factors, e.g, oral contraceptive 
use and pregnancy. The factor V Leiden mutation reduces the ability of protein C to 
inactivate factor V. This reduced deactivation of factor V results in a prolonged activation 
of the coagulation system. The prothrombin mutation is less common than FVL, about 2% 
of the Caucasian population carries this mutation13. The PT20210A mutation is associated 
with elevated levels of prothrombin. PT20210A increases the risk of venous thrombosis 
about 3-fold13. Several other single nucleotide polymorphisms (SNPs) have been described 
to mildly increase the risk of venous thrombosis with relative risks varying from 1.2 to 414. 
Known acquired risk factors are increasing age, oral contraceptive use, pregnancy, surgery, 
minor injuries, trauma, hormone replacement therapy, long haul flights, malignancies, and 
immobilization7,15–18. They are either associated with stasis or a prothrombotic state by affecting 
the coagulation system. Most of these factors are known to interact with genetic risk factors 
increasing the risk of venous thrombosis even further19,20. Despite this extensive knowledge on 
risk factors, the cause of venous thrombosis remains unknown in about one third of patients. 
Recurrent venous thrombosis
After a first venous thrombosis 15-40% of the patients will experience one or more recurrent 
events within 5 years3,21–24. Treatment with anticoagulation therapy after a venous thrombosis 
stops the clot from growing but does not dissolve it. The period in which the clot will be 
completely dissolved, if ever, depends on the size of the clot and differs per patient. Therefore, 
when a patient develops new symptoms after discontinuation of treatment for venous 
thrombosis it is often difficult to distinguish between old and new thrombi.  In the literature, 
varying definitions of recurrence are used. Some studies perform regular ultrasounds to 
follow the dissolving of the clot, or growth of an old clot as proof of a recurrence25,26. Some 
studies define a recurrence as a thrombus found in patients who have new complaints after 
the first event, while others provide no definition at all27,28. However, most studies agree on 
defining as a recurrent event a thrombus in a new vein segment compared to the first event 
found on ultrasound22,29–35. This last definition might be incorrect when a first event was a 
thrombus of the leg and recurs as a pulmonary embolism. In theory the partly dissolved 
clot, which caused the first event, could be dislodged and causing the pulmonary embolism. 
While this would then need to be classified as the first event, it may easily be regarded as a 
recurrence. Due to these difficulties in diagnosis and differences in definition of recurrence 
the incidence of recurrent venous thrombosis varies widely in the literature. 
Risk factors for a recurrent event seem to be different from those for a first event. Some of 
these differences can easily be explained because risk factors were of a transient nature or 





injuries and pregnancy22). However, age, which is one of the major risk factors does not 
seem to increase the risk of recurrence, nor do genetic prothrombotic abnormalities36–39. 
The main risk factors for recurrence, which are currently known, are male sex and an 
idiopathic first event. Sex is not a major risk factor for first venous thrombosis. For a first 
venous thrombosis the risk is higher in women up to the age of 40 than in men, after the 
age of 40 the risk is higher in men than in women. Although it may seem that the difference 
in recurrence risk can easily be explained by discontinuation of oral contraceptives and 
prophylaxis during subsequent pregnancies, previous studies showed that this does not 
explain the difference in risk between men and women for a recurrent event36,40.   
Venous thrombosis of the upper extremity
Venous thrombosis of the upper extremity is a rare form of venous thrombosis that is present 
in 4% of all patients with venous thrombosis41. Risk factors for this form of thrombosis are 
mainly similar to those for venous thrombosis of the leg. However, venous thrombosis of 
the upper extremity is most frequently caused by either a central venous catheter or the 
Paget-Schrötter syndrome42–44, which factors are specific for the upper extremity. 
Study populations
MEGA study
The Multiple Environmental and Genetic Assessment study of risk factors for venous 
thrombosis (MEGA study) is a large case-control study with over 5000 cases and over 5000 
controls. Consecutive patients aged between 18-70 (n=5170) with a first venous thrombosis 
of the leg, arm, or pulmonary embolism were collected at six anticoagulation clinics in 
the Netherlands (Amersfoort, Amsterdam, Leiden, Rotterdam, The Hague, and Utrecht) 
between March 1999 and September 2004. Control subjects were either partners of the 
patients (n=3297) or were collected via random digit dialing (RDD) (n=3000), RDD controls 
came from the same area as the anticoagulation clinics and were frequency matched by age 
and sex to the cases. Patients and controls were asked to fill in an extensive questionnaire 
about their medical history and potential risk factors for venous thrombosis. Until June 
2002, all participants were asked to provide a blood sample. From June 2002 onwards only 
DNA samples were taken with buccal swabs. Blood samples of patients were drawn at least 3 
months after discontinuation of anticoagulation treatment or, when treatment was continued 
for more than one year, approximately one year after the thrombotic event. Partners of the 
patients provided blood samples at the same time as the case. Controls from the random 
digit dial group provided blood samples within a few weeks after the questionnaire was sent. 
MEGA follow-up study
The MEGA follow-up study is a follow-up of the participants of the MEGA study described 





Additionally, all cases and controls were followed in time with a median follow-up of five 
years. All patients and controls that indicated they were willing to participate in a follow-up 
study at the initial MEGA study were sent follow-up questionnaires between June 2008 
and June 2009. These questionnaires comprised, for all participants, questions about the 
occurrence of arterial thrombosis and potential risk factors for both arterial and venous 
thrombosis. For the cases additional questions were added about the post-thrombotic 
syndrome and recurrent venous thrombosis. Recurrent events were adjudicated with 
information from discharge letters and anticoagulation clinics. The aim of the MEGA 
follow-up study was to assess the incidence of recurrent venous thrombosis, to identify new 
risk factors for a recurrent venous thrombosis, and to study the association between venous 
and arterial thrombosis and their common risk factors. 
Outline thesis
This thesis focuses on risk factors for a first and recurrent venous thrombosis of both the 
lower and upper extremity. Chapter 2, 3 and 4 concern the risk of thrombosis of the upper 
extremity and the risk factors for recurrence in these patients. In chapter 2 the current state of 
knowledge regarding risk factors for venous thrombosis of the upper extremity is reviewed. 
Blood type non-O and increased levels of FVIII, FXI and FIX are known to increase the 
risk of a first venous thrombosis of the leg. However, this had not been studied for venous 
thrombosis of the arm. In chapter 3 we investigate the influence of blood group and levels 
of coagulation factors on the risk of a first venous thrombosis of the upper extremity. In 
chapter 4 risk factors for a recurrent venous thrombosis after a first venous thrombosis of the 
upper extremity are studied. About 15% of the patients die shortly after a venous thrombosis 
event. However, the long-term effect on mortality in these patients was not well known.
Chapter 5, 6, 7 and 8 concern venous thrombosis of the leg. Both risk factors for a first and 
recurrent event, and the survival after a first venous thrombosis were studied. In chapter 5 
we describe the long-term mortality after a first venous thrombosis. From chapter 5 we 
learned that patients with a first venous thrombosis had a 3.5-fold increased risk to die 
of chronic obstructive pulmonary disease (COPD). In chapter 6 we studied COPD as a 
risk factor for a first venous thrombosis. The incidence and definition of recurrent venous 
thrombosis varies widely in the literature. In chapter 7 we describe the incidence of a 
recurrent event in detail as well as the influence of sex, age and an idiopathic first venous 
thrombosis on recurrence. In chapter 8 we examine body height as a risk factor for both 
first and recurrent venous thrombosis for both men and women; until now this association 
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Summary
Venous thrombosis of the upper extremity is a rare disease. Therefore, not as much is known 
about risk factors, treatment and the risk of recurrence as for venous thrombosis of the leg. 
Only central venous catheters and strenuous exercise are commonly known risk factors 
for an upper extremity venous thrombosis. In this review an overview of the different risk 
factors, possible treatments and the complications for patients with a venous thrombosis of 
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Introduction
Venous thrombosis of the upper extremity (UEDVT), defined as a thrombus in the 
subclavian, axillary or brachial vein, accounts for 4-10% of all venous thromboses45–50. This 
figure may be an underestimation given that UEDVT is often asymptomatic44,51,52. The low 
incidence of UEDVT compared with the leg may be explained by the lower gravitational 
stress. Additionally, the veins of the upper extremities contain fewer valves than the legs 
which could be potential foci for thrombus formation. Furthermore, stasis contributing to 
the occurrence of thrombosis is very rare in the upper extremity. The most likely conditions 
for stasis to occur are surgery and plaster cast of the upper extremity41,52.
Primary venous thrombosis
UEDVT is usually divided into primary and secondary thrombosis48,53. Primary UEDVT 
includes idiopathic thrombosis and thrombosis associated with the thoracic outlet 
syndrome or effort (Paget-Schrötter syndrome)42,43. The incidence of primary UEDVT is 2 
per 100 000 person-years46,54 and accounts for approximately 30% of all UEDVT48,54,55. 
Thoracic outlet syndrome (TOS) relates to various forms of compression in the thoracic 
outlet. The thoracic outlet is located between the base of the neck and the axilla. Compression 
of the thoracic outlet can either be on the brachial plexus or on the blood vessels in the 
outlet. Compression of both nerves and vessels is rare. In approximately 3-10% of the cases, 
TOS will be vascular which can be divided into venous or arterial TOS56. UEDVT can be 
caused by venous TOS. In venous TOS the thoracic outlet veins are compressed by the 
clavicle and the first rib57. This will result in compression or sudden occlusion of the vein. 
Approximately 60% of patients with primary UEDVT have the thoracic outlet syndrome47. 
Treatment consists of either anticoagulation alone or in combination with resection of the 
first rib57,58. Paget-Schrötter syndrome, also called effort thrombosis, is a manifestation of 
TOS. The syndrome mostly occurs in young healthy persons, related to strenuous activity 
of the arm during sports59–65. The effort causes microtrauma of the vessel intima by repeated 
compression of the clavicle and first rib, which activates the coagulation46. The compression 
is mostly caused by trauma or by the enlarged muscles in the shoulder girdle48,56,58,60,64,66.
Secondary venous thrombosis 
Secondary UEDVT is thrombosis with a known risk factor. These risk factors can be genetic 
or acquired53,67,68.
Central venous catheters
The main risk factor for UEDVT is a central venous catheter(CVC)49,67. The catheters 
are used to provide chemotherapy, medication and parenteral nutrition and for 
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the incidence and risk factors for UEDVT in patients with a CVC, as well as prophylaxis 
to prevent thrombosis69–77.
CVCs can be divided into peripherally inserted catheters, chest catheters and pacemakers. 
Peripherally inserted catheters have an incidence of thrombosis from 10% to 38%69,70,77. 
The incidence of UEDVT for chest catheters ranges from 2% to 41%71,72,75,77. The risk of 
thrombosis is dependent of the diameter of the catheter; a larger diameter gives a higher 
risk of thrombosis70. The risk of UEDVT is lower for polyurethane and silicone catheters 
compared with polyethylene or Teflon-coated catheters78,79. 
Pacemakers give thrombosis in 10%. This risk increases with the number of leads from the 
pacemaker80,81. Most occlusions occur within the first 2 months after insertion of the catheter70,82,83.
Malignancy 
Malignancy is an important risk factor for UEDVT. However, the increased risk in patients 
with malignancy is mainly induced by CVCs Dhami & Bona, 1993; Girolami, Prandoni, 
Zanon, Bagatella, & Girolami, 1999)86. In the Multiple Environmental and Genetic Assessment 
(MEGA) study of risk factors for venous thrombosis, a population-based case-control study, 
179 patients with UEDVT were compared to 2399 control subjects. In patients without a 
CVC with an active form of malignancy an 18-fold increased risk of UEDVT compared 
with patients without active malignancy was found. Active malignancy was defined as 
malignancy diagnosed 5 years or less before first venous thrombosis86. A 7.7-fold increased 
risk of UEDVT was found when all, active and inactive, malignancies were included. 
Coagulation abnormalities and genetic risk factors
In the literature the prevalence of coagulation abnormalities in patients with UEDVT ranges from 
8% to 61%45,68,87,88. The differences can be explained by the size of these studies, including only 
between 18 and 51 patients. Additionally, the studies had different time points of blood collection: 
at diagnosis of thrombosis, 3 weeks after the event or after discontinuation of anticoagulation 
therapy. This can influence the assessment of coagulation abnormalities. Only antiphospolipid 
antibodies seem consistently more frequently present compared to the healthy population87–89.
Factor (F) V Leiden12 and the prothrombin 20210AP13 mutation are common genetic 
risk factors in venous thrombosis of the leg, and may be a risk factor for UEDVT. Some 
studies reported an increased risk for either factor V Leiden or the prothrombin 20210A 
mutation or both. An Italian study included 115 patients with an UEDVT and 797 control 
subjects. A 5- to 6-fold increased risk of UEDVT was found for patients with one of the 
mutations90. In a Spanish study of 79 cases and 165 controls an increased risk was found 
for patients with the prothrombin 20210A mutation, no effect was found for the FV Leiden 
mutation53. A follow-up study including 257 patients with a CVC found a 3-fold increased 
risk of a UEDVT in patients with a mutation compared with patients without a mutation74. 
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FV Leiden or prothrombin 20210A mutation, the number of patients in these studies was 
small. Therefore, no solid conclusions can be drawn. 
Oral contraceptive use, surgery and plaster cast
Oral contraceptive use did not increase the risk of UEDVT in most studies48,87,90,91. However, in 
a Spanish study a 5.7-fold (CI: 2.1-15.7) increased risk was found, and the MEGA study found 
a 2-fold (CI: 1.1-3.8) increased risk53,86. So, there is no consensus about oral contraceptive use 
as risk factor for UEDVT. Differences may be explained by the type of patients included in the 
studies. A study including patients with a primary UEDVT showed an increased risk while 
studies including patients with secondary UEDVT did not show an effect of oral contraceptives. 
Surgery and plaster cast of the upper extremity result in stasis in the upper extremity. Only 
one study investigated surgery and plaster cast as a risk factor of UEDVT. This study found 
surgery of the upper extremity as a risk factor with an odds ratio of 13.1 (95% CI 2.1-80.6)86. 
Plaster cast of the arm increased the risk with an odds ratio of 7.0 (95% CI 1.7-29.5)86.
Other risk factors
Other possible risk factors for UEDVT are obesity, hormone replacement therapy (HRT) 
and pregnancy. Few studies have investigated these risk factors. Obesity and HRT were 
no risk factors86,92. A case series reported pregnancy, especially in combination with ovary 
hyperstimulation syndrome, as a risk factor in women for UEDVT93. However no large 
studies were performed to assess the thrombotic risk for pregnancy. 
Treatment
Unfortunately, no randomised controlled trials have been performed on the optimal 
treatment for patients with UEDVT. Therefore, there is still debate about what the best 
therapy is and how side effects can be minimized. Anticoagulation is the most common 
treatment with a similar strategy as for deep vein thrombosis of the leg consisting of low 
molecular weight heparin and vitamin K antagonists. Removal of the main risk factor, for 
instance a CVC, probably reduces the risk of a recurrent event. However, in most cases 
removal of the CVC is not possible and therefore is inserted in the other arm or on the 
opposite site of the chest. Thrombolysis, surgery, thrombectomy and balloon dilatation with 
and without stent placing are used far less94–98. In these cases removal of a rib or correction of 
malformations of the ribs or clavicle may be part of the treatment. However, these aggressive 
forms of treatment may have serious side effects. Thrombolysis gives a higher risk of 
bleeding and surgery can cause pneumothorax, nerve damage and rethrombosis98,99. Balloon 
thrombectomy and venous stents can cause thrombosis by inducing intima damage97. In 
several pilot studies thrombolysis was compared with standard anticoagulation therapy in 
patients with a UEDVT. Most patients reacted well to thrombolysis and there were only a few 
more bleedings compared to the standard treatment100–102. A clear advantage of thrombolytic 
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venous thrombosis showed no difference in outcome after 3 months of therapy in patients 
with a deep vein thrombosis of the upper extremity or of the leg103. However, in this study 
treatment for UEDVT was different from that for thrombosis of the leg. Approximately 
50% of the patients with UEDVT were only treated with low molecular weight heparins 
for 3 months and the other half with vitamin K antagonists. In venous thrombosis of the 
leg 70% of patients were treated with vitamin K antagonists. Therefore, the groups in this 
registry were not entirely comparable. These results show that patients with UEDVT with 
their current treatment have the same prognosis after three months as patients with venous 
thrombosis of the leg. Whether this is the most optimal treatment remains unclear.  
Complications
The main complications of UEDVT are pulmonary emboli (30%), post-thrombotic 
syndrome (PTS) and death55,87,104–106. PTS occurs in 7-44% of patients55,107,108 (table 1). These 
percentages are based on small studies with different definitions of PTS. Mortality ranges 
from 15 to 50%, and is high because of major co-morbidity (e.g., malignancy, infection and 
multi-organ failure)48,106,108. 
In a few small studies the annual recurrence rate after a first UEDVT was 2% to 8%. 
However, groups were small and only one study found thrombophilia as possible risk factor 
for a recurrence; the other studies were too small to identify risk factors90,106,108. 











Hingorani 199755 170 39 68 (9-101) Both 7% - 34%
Prandoni 199787 27 70 53 (19-79) Both 15% 7% 15%
Martinelli 200490 96 36 32 (14-61) Primary - 2% -
Baarslag 2004106 50 42 52 (23-86) Both 18% 8% 50%
Prandoni 2004108 53 31 44 -- Both 20% 2% 20%
Hingorani 2005 546 40 68  (1-101) Both - - 29%
Kahn 2005109 34 46 51 (22-86) Both 44% - -
Hingorani 2006104 598 38 69 (9-101) Both - - 29%
Conclusion
UEDVT is a rare disease that mainly occurs in patients with a CVC. Most other risk factors 
are the same as for patients with a venous thrombosis of the leg. Mortality, pulmonary 
embolism and PTS are the most important complications of UEDVT but the incidences of 
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T: effect of blood group and coagulation factor levels
Summary
Venous thrombosis of the upper extremity is a rare form of thrombosis, accounting for 
around 4 percent of all venous thromboses, of which only a few risk factors are known. 
The aim of this case-control study was to investigate the effect of coagulation factors on 
risk of venous thrombosis of the upper extremity. Patients with venous thrombosis of 
the arm and partner controls were selected from the MEGA study, a large population-
based case-control study. Participants with a malignancy were excluded. Odds ratios were 
estimated for elevated levels of factor II, VII, VIII, IX, X, XI, von Willebrand Factor (vWF), 
and fibrinogen, low levels of protein C, protein S, and antithrombin, and for blood group 
non-O. Substantially increased risks of venous thrombosis of the upper extremity were 
found for patients with high levels (above 90th percentile vs below) of factor VIII (Odds 
ratio (OR): 4.2, 95% confidence interval (CI): 2.2-7.9), vWF (OR: 4.0, 95% CI: 2.1-7.8), 
fibrinogen (OR: 2.9, 95% CI, 1.5-5.7), and for blood group non-O compared to O (OR: 2.1, 
95% CI, 1.3-3.6). The other factors were not associated with an increased risk. Elevated 
levels of several procoagulant factors are associated with a strongly increased risk of venous 
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Introduction
Only 4 % of all cases of venous thrombosis are located in the upper extremity41,51</sup>. 
Therefore, most studies on risk factors for venous thrombosis focused on venous thrombosis 
of the leg or pulmonary embolism and only a few studies investigated the risk of venous 
thrombosis of the upper extremity, often restricted to a small number of risk factors. 
Malignancy, a central venous catheter, oral contraceptive use, surgery of the upper 
extremity, physical activity of the arm and the factor V Leiden12 and prothrombin 20210A13 
mutation are known to increase the risk of venous thrombosis of the upper extremity in 
several studies, including the MEGA study44,53,63,72,77,85,86,90.
Individuals with elevated levels of procoagulant factors II, VIII, IX, and XI have an increased 
risk of venous thrombosis of the leg, with two- to threefold increased risks for those in the 
highest 10 percent of the population distribution13,110–112. Furthermore, blood group non-O is 
associated with a two-fold increased risk of venous thrombosis of the leg113. Only a few studies 
investigated the effect of procoagulant factors in patients with venous thrombosis of the upper 
extremity. Two studies examined the effect of factor VIII and fibrinogen. High levels of factor 
VIII were found to be present in the same number of patients with venous thrombosis of the 
upper extremity as in patients with venous thrombosis of the leg114. Similarly a high prevalence 
of high levels of fibrinogen was found115. However, in both studies no comparisons with the 
general population were made and hence no risk estimates were reported.
Deficiencies of anticoagulants protein C, protein S, and antithrombin substantially increase 
the risk of venous thrombosis of the leg116. Studies on the association of these defects with 
upper extremity thrombosis are scarce and have yielded conflicting results45,88,91,94. 
The aim of this study was to investigate the levels of pro- and anticoagulant factors and 
blood group as risk factors for venous thrombosis of the upper extremity.
Methods
Study population
Analyses were performed as part of a large population-based case-control study. Patients 
and control subjects were selected from the Multiple Environmental and Genetic 
Assessment (MEGA) study of risk factors for venous thrombosis. Details of this study have 
been described elsewhere7. In the overall study over 5000 consecutive patients with deep 
venous thrombosis of the leg, a pulmonary embolism, or a venous thrombosis of the upper 
extremity between the age of 18 and 70, and their partners (>3000) were included. Patients 
were treated in 6 anticoagulation clinics in the Netherlands.
From March 1999 until September 2004, 329 consecutive patients with a venous thrombosis 
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were no differences in sex and age between those who did and did not participate. Blood 
was obtained from patients and control subjects included up to July 2002. Since the risk 
factors in the current study involve plasma factor levels, a blood sample is necessary. 
Consequently, 107 patients and 1825 controls were eligible for this study. Venous thrombosis 
was objectively confirmed with either ultrasonography, duplex sonography or computed 
tomography. Partners of patients with venous thrombosis in the overall study were included 
as control subjects. These were therefore partners of patients with different types of venous 
thrombosis, including deep-vein thrombosis of the leg and pulmonary embolism. Control 
subjects did not have a history of venous thrombosis and were between 18 and 70 years. 
Individuals with a malignancy (31 cases and 57 controls) and individuals without a blood 
sample (7 cases and 329 controls) were excluded from the present study. In total 69 patients 
with a venous thrombosis of the upper extremity and 1439 control subjects were included.
Data collection
All participants were asked to fill in a questionnaire on acquired risk factors for venous 
thrombosis within a few weeks after the index date. For patients the index date was date 
of the thrombotic event. For control subjects the index date was the date of diagnosis of 
thrombosis of their partner. Oral contraceptive use was considered to be present when 
used within 3 months before the index date. Idiopathic venous thrombosis was defined as 
present when occurring in the absence of factor V Leiden, prothrombin 20210A mutation, 
oral contraceptive use, surgery, plaster cast and, injury within 3 months before thrombosis, 
central venous catheter within a month before thrombosis and pregnancy or puerperium 
(< 5 weeks after delivery) at time of thrombosis. Both patients and control subjects were 
invited for a blood draw and interview at least 3 months after discontinuation of vitamin K 
antagonist treatment of the patient. Infection was present when patients reported a febrile 
disorder at time of blood draw. When duration of treatment was more than one year patients 
were invited for a blood draw at least 12 months after the thrombotic event. The mean time 
between index date and blood draw was 10 months for cases (range 4-24 months) and 7 
months for controls (range 1-34 months).
All participants filled in an informed consent form and gave permission to obtain 
information about their medical history. This study was approved by the Ethics Committee 
of the Leiden University Medical Center, the Netherlands.  
Laboratory measurements
Blood samples were drawn into vacuum tubes containing 0.1-volume 0.106-mol/L trisodium 
citrate as anticoagulant. Activity of factor II, VII, VIII, X, and XI was measured with a mechanical 
clot detection method on a STA-R coagulation analyzer. All measurements were performed 
following the instructions of the manufacturer (Diagnostica Stago, Asnières, France). Levels 
of factor IX antigen were determined by enzyme-linked immunosorbent essay (ELISA). Von 






T: effect of blood group and coagulation factor levels
STA liatest kit (rabbit anti human VWF antibodies). Fibrinogen activity was measured on the 
STA-R analyzer according to the method of Clauss. The 20146G/- (rs8176719), 21463C/G 
(rs7853989), 21867A/G (rs8176749), and 21996C/- (rs8176750) blood group polymorphisms 
were determined by a 5’nuclease assay (Taqman; Applied Biosystems, Foster City, California) 
using a standard PCR reaction mix (Eurogentec, Seraing, Belgium) and an allele specific 
fluorescent probe equipped with a minor groove binding moiety (Applied Biosystems). 
Definitions of low levels of antithrombin, protein S, and protein C have been described 
elsewhere117. In brief, protein C, protein S, or antithrombin deficiency was defined as value 
below the mean minus two standard deviations in the control subjects. Due to unreliable 
test results, individuals with a blood sample at time of pregnancy were excluded from the 
analysis of protein C and protein S. The same applied to individuals using oral contraceptives 
at time of the blood sample in the determination of protein S. Sixty-six out of 69 patients 
and 1430 out of 1439 controls are left for the analysis of protein C and 57 patients vs. 
1322 controls for protein S. The risk of vitamin K dependent factors was determined for 57 
patients with a blood draw after discontinuation of vitamin K antagonist treatment. There 
were no missing data for the pro- and anticoagulant factors. 
Statistical analysis
Odds Ratios (OR) and 95% confidence intervals were calculated as an estimate of the risk of 
venous thrombosis associated with coagulation factor levels and blood group non-O. Odds 
Ratios were adjusted for age and sex with a logistic regression model. The 90th percentile 
in the control subjects was used as cut off point for factors II, VII, VIII, IX, X, and XI, 
von Willebrand factor (VWF), and fibrinogen. For those factors with an increased risk 
for patients above the 90th percentile, tertiles were defined on the basis of the distribution 
among control subjects to investigate a dose response relation using the lowest tertile as a 
reference. Individuals with blood group non-O were compared with individuals with blood 
group O. The thrombotic risks associated with elevated factor VIII and VWF levels, and 
blood group were mutually adjusted. Since previous research found a joint effect of factor 
VIII and oral contraceptive use in patients with a venous thrombosis of the leg, the joint 
effect of factor VIII above the 90th percentile with oral contraceptive use among women was 
assessed118–120. Participants with low factor VIII and without oral contraceptive use at the 
time of index date were used as a reference group. The joint effect was adjusted for age. All 
analyses were performed using SPSS 14 (SPSS Inc, Chicago, Ill).
Results
There were slightly more men in the control group than in the patient group: 49 versus 44 
percent. Median age of the 69 patients was 39 (5th-95th percentile 21-65 years) compared with 51 
(5th-95th percentile 29-66 years) in the 1439 controls (table 1). The prevalence of infection was 
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Mean levels of procoagulant factors in patients with venous thrombosis of the upper 
extremity and control subjects are shown in table 2. Mean levels of factor VIII, VWF and 
fibrinogen were higher among the cases. All other procoagulant factors were similar in cases 
and controls or even higher in the control than the case group. The distribution of blood 
group differed for cases and controls. After dichotomization by the 90th percentile, elevated 
levels of factors II, VII, IX, and X were not associated with an increased risk of an upper 
extremity venous thrombosis (table 3). Mean levels of factor VIII, VWF, and fibrinogen 
were higher in patients than in controls (mean difference: factor VIII (21.7IU/ml, 95%CI, 
Table 1. Baseline characteristics of the study population, including 69 patients with a venous 
thrombosis of the upper extremity and 1439 control subjects.
Patients N (%) Controls N (%)
Sex (% men) 30 (44) 706 (49)
Median age (years) 39 51
CVC* 4 (6) 0 (0)
Infection% 19 (27) 321 (23)
WBC* (mean, SD) 5.6 (1.4) 5.7 (1.7)
Idiopathic thrombosis 22 (32) -
Oral contraceptive use# 24 (62) 131 (18)
*CVC=Central venous catheter, WBC=White blood cell count
# In women (24 out of 39 cases, 131 out of 733 control subjects) at time of the index date 
% At time of blood sample
Table 2. Mean levels of procoagulant factors and the prevalence of blood group in 69 patients and 
1439 control subjects
Mean level coagulation factor
Patients Controls 
Mean (SD)* Mean (SD)*
FII† 98 (35) 111 (18)
FVII† 91 (35) 112 (25)
FVIII 131 (44) 109 (37)
VWF 138 (68) 113 (49)
FIX† 102 (20) 106 (19)
FX† 100 (42) 117 (20)
FXI 100 (19) 101 (20)
Fibrinogen 4.0(0.8) 3.0(0.6)
Blood group (%) (%)
O 32 47
Non-O 68 53
Factor II, VII, VIII, X, and XI were expressed in IU/ml; VWF and fibrinogen in g/l; factor IX in U/dl.
*SD= standard deviation
†Vitamin K dependent factors, figures were calculated after exclusion of patients using vitamin K antagonist 
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12.7-30.7), VWF (24.8 g/l, 95%CI, 12.7-36.9), and fibrinogen (0.1 g/l, 95%CI, 0.01-0.3)). 
Elevated levels of fibrinogen were found in 19% of patients i.e. over 4.15 g/l. An elevated 
level of fibrinogen (i.e. above the 90th percentile) was associated with a 2.9-fold (95% 
CI: 1.5-5.7) increased risk of thrombosis compared with low levels (below 90th percentile), 
after adjustment for age and sex.
Twenty-two percent of the patients had an elevated level of factor VIII, i.e. over 155 IU/ml 
(table 3). Individuals with an elevated level of factor VIII had a 4.2-fold (95% CI: 2.2-7.9) 
increased risk compared with those with low levels after adjustment for age and sex.
Twenty percent of patients had an elevated level of VWF, i.e. over 170 g/l. Individuals with 
elevated levels of VWF had a 4.0-fold (95% CI: 2.1-7.8) increased risk of venous thrombosis 
compared to those with low levels after adjustment for age and sex. 
Of all patients, 68% had blood group non-O compared with 53% of all controls. Blood 
group non-O was associated with a 2.1-fold (95% CI: 1.3-3.6) increased risk of venous 
thrombosis compared with blood group O, after adjustment for age and sex. Associations 
between factor VIII, VWF and blood group non-O have been described previously110. 
In control subjects, levels of factor VIII and VWF differed between blood group O and 
non-O. The mean difference for individuals with blood group O compared with non-O 
for factor VIII was 34 IU/ml (95% CI: 30-39), for VWF the mean difference was 37 g/l 
(95% CI: 32-41). In a model with blood group, von Willebrand factor and factor VIII levels, 
all effects were attenuated, particularly those of factor VIII (OR 1.7, 95%CI (0.7-3.6) and 
Table 3. The risk of venous thrombosis of the upper extremity for procoagulant factors 
Procoagulant 
factor
90th percentile  
cutt-off point
N of patients >90th 
percentile (%) OR (95% CI)
Adjusted OR (95% 
CI)*
FII† 129.0 IU/ml 5(9) 1.0 (0.4-2.5) 0.9 (0.4-2.3)
FVII† 145.0 IU/ml 2(4) 0.3 (0.1-1.4) 0.5 (0.1-1.9)
FVIII 155.0 IU/ml 15(22) 2.5 (1.4-4.6) 4.2 (2.2-7.9)
VWF 170.0 g/l 14(20) 2.5 (1.4-4.6) 4.0 (2.1-7.8)
FIX† 131.1U/dl 5(9) 0.9 (0.3-2.2) 1.1 (0.4-2.7)
FX† 141.0 IU/ml 5(9) 0.9 (0.4-2.3) 0.9 (0.3-2.3)
FXI 126.0 IU/ml 8(12) 1.3 (0.6-2.7) 1.5 (0.7-3.2)
Fibrinogen 4.15 g/l 13(19) 2.2 (1.2-4.2) 2.9 (1.5-5.7)
Blood group
N of patients blood group 
non-O OR (95% CI)
Adjusted OR (95% 
CI)*
Non O vs. O - 47(68) 1.9 (1.1-3.2) 2.1 (1.3-3.6)
*Adjusted for age and sex 
†Vitamin K dependent factors, figures were calculated after exclusion of patients using vitamin K antagonist 
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VWF (OR 1.9, 95%CI (0.8-4.7)), while blood group non-O remained associated with an 
1.7-fold risk (95% CI: 1.0-2.8). None of the patients had a protein S deficiency. Only one 
patient had low protein C levels and only one patient low antithrombin levels. Therefore, 
the thrombotic risk for these anticoagulant factors could not be estimated.
Increased risks of venous thrombosis were seen for elevated levels of factor VIII, VWF, and 
fibrinogen. To explore a dose response relation between the levels of these factors and the 
risk of venous thrombosis, factor levels were divided in tertiles. Cut-off values for tertiles (in 
the controls) and risk estimates are shown in table 4. With the lowest tertile as a reference 
category, there was a clear dose response relation for both VWF and factor VIII levels. For 
fibrinogen levels both the second and third tertile showed similarly increased risks. 
Since many female patients were using oral contraceptives at time of the thrombotic event 
and previous studies showed a high joint effect of oral contraceptive use and elevated factor 
VIII levels in patients with a venous thrombosis of the leg, we considered the possibility of 
a synergistic effect between elevated levels of factor VIII and oral contraceptive use. Results 
are shown in table 5. An elevated level factor VIII alone as well as use of oral contraceptive 
use only, were associated with an increased risk of venous thrombosis of the upper extremity 
(OR 5.3, 95%CI (1.3-20.5) and 7.5, 95%CI (2.2-25.5) respectively). The thrombotic risk 
was highest for women with both elevated levels of factor VIII and oral contraceptive use 
(OR 30.5, 95%CI (8.8-105.7)). 
Table 4. Factor VIII, VWF, and fibrinogen and the risk of venous thrombosis of the upper extremity
Coagulation factor   
(cut-off points for tertiles) 1st Tertile 2nd Tertile* 3rd Tertile*
Factor VIII (89, 120) 1# 2.2 (1.3-3.9) 8.8 (3.9-19.8)
VWF (87, 122) 1# 2.0 (1.1-3.5) 5.9 (2.8-12.2)
Fibrinogen (3.0, 3.5) 1# 2.5 (1.3-4.9) 2.3 (1.2-4.1)
* Adjusted for age and sex
# Reference category
Table 5. Joint effect of factor VIII and oral contraceptive use and the risk of thrombosis in the upper 
extremity.
Oral contraceptive use High factor VIII Patients N Controls N OR (95% CI)*
- - 9 523 1#
+ - 18 122 5.3 (1.3-20.5)
- + 6 79 7.5 (2.2-25.5)
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Discussion
In this study we assessed the association between levels of pro- and anticoagulant factors 
and blood group and the risk of venous thrombosis of the upper extremity. Elevated levels 
of factor VIII, VWF, fibrinogen, and blood group non-O increased the risk of a venous 
thrombosis of the upper extremity. Elevated levels of factor II, factor VII, factor IX, factor 
X, and factor XI were not associated with an increased risk. We were not able to assess the 
risk of venous thrombosis of the upper extremity associated with protein C, protein S, or 
antithrombin deficiency.
The overall prevalence of deficiencies of anticoagulant factors protein C, protein S, and 
antithrombin among patients in several studies varies between 2% up to 12%88,89,92. In the 
current study no patients with protein S deficiency were identified; only one patient had a 
protein C deficiency, and only one patient was antithrombin deficient (both 3%). Given that 
the population prevalence of these abnormalities varies between 0.2% (protein C deficiency) 
and 0.02% (antithrombin deficiency), our findings are compatible with highly increased risks. 
After dichotomization at the 90th percentile as measured in the control subjects, elevated 
levels of factor VIII, VWF, and fibrinogen were found to increase the risk of a first venous 
thrombosis of the upper extremity. There was also a clear dose response relation for factor 
VIII and VWF after stratification of the levels in tertiles. For fibrinogen no gradual increase 
in risk over the tertiles was observed. 
Factor VIII, VWF, and fibrinogen are acute phase proteins. Therefore the question rises 
whether the elevated levels are a cause or consequence of venous thrombosis of the upper 
extremity. Blood was drawn at least 4 months after venous thrombosis. When comparing 
patients with a blood draw within one year with those with a blood draw more than one year 
after the thrombotic event, levels of factor VIII, VWF, and fibrinogen were similar (mean 
differences: factor VIII (2.4 U/dl, 95%CI, -21.8-26.6), VWF (0.9 U/dl, 95%CI, -36.4-38.2), 
and fibrinogen (-0.2 g/l, 95%CI, -0.6-0.3)). Furthermore, the prevalence of reported febrile 
disorders at time of blood draw and mean white blood cell count were similar between patients 
and controls. Finally, the effect of blood group is likely to be mediated via von Willebrand 
factor and factor VIII levels, and of course invariant. These results indicate that it is unlikely 
that the elevated levels of factor VIII, VWF, and fibrinogen are due to an acute phase reaction, 
which corroborates what has been proposed before for patients with venous thrombosis of 
the leg121. Thus, elevated levels of factor VIII, VWF, and fibrinogen are likely to be a cause of 
venous thrombosis of the upper extremity rather then a consequence of the disease.
Blood group non-O was associated with a two-fold increased risk of venous thrombosis of 
the upper extremity. After adjustment for factor VIII and VWF the risk of venous thrombosis 
of the upper extremity for blood group non-O compared with O was similar to the crude risk 
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different pathway than factor VIII and VWF levels. After additional adjustment for blood-
group and VWF or factor VIII, the risk of venous thrombosis associated with elevated factor 
VIII levels decreased from a 4.2 to a 1.7-fold increased risk, whereas the risk associated with 
elevated VWF levels decreased from a 4.0 to a 1.9-fold increased risk. This shows that the 
effect of factor VIII and VWF is partly due to the effects of blood group non-O.
There was a synergistic effect seen for high levels of factor VIII and oral contraceptive use, 
which was supra-additive.
This is the first study that assessed the risk of venous thrombosis of the upper extremity 
associated with elevated procoagulant factors. Although the number of patients was low 
due to the exclusion of individuals with a malignancy, we found an increased risk of 
upper extremity thrombosis for patients with an elevated level of factor VIII, VWF, and 
fibrinogen. The results for VIII, VWF, fibrinogen, and blood group non-O were similar 
to results found for venous thrombosis of the leg. Due to the small number of patients 
with anticoagulant protein C, protein S, and antithrombin deficiency, we were unable to 
estimate the risk of venous thrombosis of the upper extremity associated with low levels of 
anticoagulant factors, although the finding of two patients among 69 with such a defect is 
highly suggestive of an increased risk. 
This study showed that elevated levels of several of the procoagulant factors are risk factors 
for both deep venous thrombosis of the leg as well as venous thrombosis of the upper 
extremity. However, there are also differences with regard to coagulation factors as risk 
factor for a venous thrombosis of the leg or of the upper extremity. Factors II, IX and XI 
have been described as risk factors for venous thrombosis of the leg but do not appear to 
increase the risk of venous thrombosis of the upper extremity in our study. This might be 
explained by the number of patients in our study. Although our study is the largest study 
investigating the effect of coagulation factors on venous thrombosis in the upper extremity 
among individuals without a malignancy, we only included 69 patients. A hypothetical 
explanation for the different coagulation factors that give an increased risk for deep venous 
thrombosis of the leg and or the upper extremity could be that venous thrombosis of the 
leg is likely to be more often induced by stasis (plaster cast, travel, hospital admission) 
and venous thrombosis of the upper extremity more often by injury of the vessel wall 
(CVCs, physical effort). In the presence of an injury of the vessel wall it might be important 
that factors related to the acute phase are elevated compared to other factors. If venous 
thrombosis is due to stasis, it might be less important which procoagulant abnormality is 
present. However, this hypothesis should be tested in a different study. 
In conclusion, we found an increased risk of venous thrombosis of the upper extremity in 
patients with an elevated level of fibrinogen, factor VIII, VWF, and in patients with blood 
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Little is known about the consequences of a first venous thrombosis in the upper extremity. 
We studied the incidence of, survival, and risk factors for recurrence in a follow-up study. 
We followed up 224 patients 18 to 70 years of age after a first venous thrombosis of the 
arm. Information was collected through anticoagulation clinics, the national death registry, 
discharge letters, and questionnaires. The median follow-up was 3 years, during which time 
30 patients experienced a recurrent event, yielding an incidence rate of 43.2 per 1000 person-
years. Survival was reduced: 55 out of 224 patients died, which was 5.4-fold higher than age- 
and sex-adjusted population rates (standardized mortality ratio 5.4; 95% CI 4.2-7.0). The risk 
of recurrence was 2-fold higher in women than in men (hazard ratio 1.8; CI 95% 0.9-3.9). 
A central venous catheter at the time of first thrombosis was associated with a reduced 
risk of recurrence. A body mass index >= 25 kg/m2 and a first non-subclavian thrombosis 
appeared to increase the risk of a recurrent event. Prothrombotic mutation carriers did not 
appear to have an increased recurrence risk. Th e risk of recurrence was high, with women, 
patients with body mass index>= 25 kg/m2, and patients with a first non-subclavian vein 
thrombosis having a higher risk of recurrence. Patients with a first venous thrombosis of 









The incidence of venous thrombosis varies between 1 per 10 000 in young adults and 1 per 100 
persons per year in the very old, with a population average of 1 to 3 per 1000 persons per year2,3. 
About 4% of all cases of venous thrombosis are located in the upper extremities41,51. Because 
of its rarity, thrombosis of the arm has not been investigated as extensively as deep venous 
thrombosis of the leg or pulmonary embolism. However, the incidence of upper extremity 
venous thrombosis increases over time90,122,123. This is mainly due to the increasing use of central 
venous catheters (CVCs) which, combined with malignancy, is the strongest determinant of 
upper extremity venous thrombosis, with >1000-fold increased risk compared with patients 
without a CVC and malignancy44,86. Besides foreign objects such as CVCs and pacemaker 
leads, the main known causes of arm thrombosis are a hypercoagulable state, as induced by 
malignancy or coagulation abnormalities, and stasis in veins. The latter can be caused by a 
variety of related syndromes, ie, trauma of the arm, effort-related compression of the deep veins 
of the upper extremity (Paget-Schrötter syndrome), and compression caused by the thoracic 
outlet syndrome41,46,68,86,90,91,124. A few of the major coagulation abnormalities appear to enhance 
the risk of arm thrombosis as they do for venous thrombosis of the lower extremities41,68. Factor 
V Leiden, Protein C and S deficiency, anticardiolipin antibodies and lupus anticoagulants are 
frequent among patients with a venous thrombosis of the upper extremity87–89,91. 
Because of the low incidence, few studies have investigated recurrent venous thrombosis 
of the arm and its risk factors90,103,106,108.  In these studies, the cumulative incidence of 
recurrence after 1 year was 2% to 5%90,106,108. Inclusion criteria and end points differed 
between studies. One study included patients with an idiopathic venous thrombosis of the 
arm and reported only venous thrombosis of the arm as a recurrent event90. Two studies 
assessed risk factors for a recurrence among patients with primary or secondary venous 
thrombosis of the arm and included all types of venous thrombosis as recurrent events106,108. 
Prothrombotic mutations appeared to be associated with a recurrent event in 1 study of 90 
patients with a first primary venous thrombosis of the arm90. However, another study did 
not confirm these results106. 
In the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis 
study (MEGA-study), 224 consecutive patients with a first venous thrombosis of the arm were 
included in the present follow-up study. The aim was to investigate survival and the incidence 
of recurrent venous thrombosis in any location in relation to risk factors such as the presence 
of a CVC, malignancy, prothrombotic mutations, and other putative risk factors.
Materials and Methods
Patient Selection
Two hundred twenty-four consecutive patients 18 to 70 years of age with a first venous 
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The MEGA study is a large population-based case-control study to assess risk factors for a 
first venous thrombosis. Details of this study have been given elsewhere7,86. Patients were 
included from the files of six anticoagulation clinics, which monitor virtually all patients 
who receive treatment with vitamin K antagonists in the Netherlands, each in a well-defined 
geographical region. A venous thrombosis of the internal jugular vein, subclavian, axillary, 
brachial or the superficial basilic and cephalic veins was considered to be an upper extremity 
venous thrombosis. Fifteen patients were also diagnosed with a pulmonary embolism or a 
venous thrombosis of the lower extremity. Venous thrombosis of the upper extremity was 
confirmed with either ultrasound, contrast venography or computed tomography86. 
Data collection
In 2006, municipal registries were contacted to retrieve the most recent addresses of 
patients and to assess vital status. Causes of death were obtained from the Central Bureau 
of Statistics Netherlands (CBS), which stores all Dutch death certificates. An inquiry form 
was sent to patients who were still alive and who had initially agreed to participate in a 
follow-up study. The inquiry form asked about subsequent visits to anticoagulation clinics 
and the occurrence of a recurrent event in any location. Patients were sent a follow-up 
questionnaire about putative risk factors for a recurrent venous thrombosis, either by mail 
or via the Internet. Patients who did not reply were contacted by phone. Information about 
recurrences and duration of initial vitamin K antagonist treatment for all 224 patients also 
was obtained from anticoagulation clinics. Recurrences were included when confirmed by 
ultrasound, contrast venography or computed tomography according to the discharge letters. 
Information regarding putative risk factors at time of first venous thrombosis was obtained 
from the baseline questionnaire and from the discharge letters of the first thrombosis7. An 
event was defined as idiopathic in the absence of surgery, oral contraceptive use, injury and 
plaster cast in the previous 3 months, malignancy, absence of CVC in the previous month, 
and absence of puerperium, factor V Leiden mutation or prothrombin 20210A mutation. 
All participants gave informed consent. This study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center, Leiden, the Netherlands. 
Blood collection and laboratory analysis
Blood samples were taken at least 3 months after discontinuation of vitamin K antagonist 
treatment for the first thrombotic event. Blood draws were collected from 67 patients. 
Blood samples were drawn into vacuum tubes containing 0.1 volume 0.106 mol L-1 
trisodium citrate as anticoagulant. Blood samples were separated into plasma and cells 
through centrifugation. Prothrombin activity, Factor VII activity, Factor VIII activity, 
Factor X activity, and Factor XI activity were measured with a mechanical clot detection 
method on a STA-R coagulation analyzer. All measurements were performed following 
the manufacturer’s instructions (Diagnostica Stago, Asnieres, France). Levels of factor IX 
antigen were determined by ELISA. Fibrinogen activity was measured on the STA-R analyzer 
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of a diluted plasma sample was measured. Von Willebrand factor antigen was measured 
with the immunoturbidimetric method, using the STA liatest kit (rabbit anti-human von 
Willebrand factor antibodies), following the instructions of the manufacturer (Diagnostica 
Stago). DNA was collected with buccal swabs from patients who were unable to give a 
blood sample and from all patients who were included beginning in June 2002. In total, 
DNA samples were collected from 178 patients. High molecular weight DNA was collected 
by using a salting-out method and stored at -20 °C until amplification. DNA-analysis of 
the factor V Leiden and prothrombin 20210A mutation was performed with a combined 
polymerase chain reaction method. Assessment of these mutations in DNA retrieved from 
buccal swabs was performed identically to the method for DNA obtained from whole blood. 
A detailed description of these methods was described previously7. 
Statistical Analysis 
Cumulative incidence was estimated by the Kaplan-Meier technique. Incidence rates 
were the number of new events over the total number of person-years. Person-years 
were calculated from date of first event and from discontinuation of the initial vitamin 
K antagonist treatment until recurrent event, death or end of study, whichever came first. 
Participants who died during follow-up of a cause other than venous thrombosis were 
censored at date of death. Patients who were not able to complete the inquiry form were 
censored at their last contact within the MEGA study and considered study withdrawals. 
The end of study date was October 1, 2006. Hazard ratios (HRs) were estimated with a Cox 
proportional-hazards model. Adjustments were made for age and sex. We did not adjust 
for race because our follow-up study included >95% whites. Cox analysis was performed in 
the overall cohort of 224 patients and in 163 patients after they had discontinued vitamin 
K antagonist treatment. Median duration of vitamin K antagonist treatment was 6 months 
(5th percentile, 2 months; 95th percentile, 57months). High levels of prothrombin, factor 
VII activity, factor VIII activity, factor IX antigen, factor X activity, factor XI activity, von 
Willebrand factor, and fibrinogen were defined as a level above the 90th percentile in the 
group of patients without a recurrent event. Standardized mortality ratios (SMRs) were 
estimated for the overall patient group with the general Dutch population as a reference125 
and in men and women separately with the sex-specific population rates as reference. These 
SMRs estimate the rate of death relative to age- and sex-adjusted rates from the general 
population or, in other words, give the ratio of the observed and expected number of deaths 
when population rates are applied to the cohort. Data from 2003 were used to represent the 
average general population of the period from 1999 till 2006. Confidence intervals were 
based on a Poisson distribution. All analyses were performed with SPSS version 14 (SPSS 
Inc, Chicago, Ill). The authors had full access to and take responsibility for the integrity of 










Of the 224 patients, 47% were men, and the median age at time of first thrombosis was 46 years 
(5th percentile, 21 years; 95th percentile, 67 years). The median follow-up period was 3 years 
(range 0 to 7.5 years). Of the 30 recurrences, 9 were during vitamin K antagonist treatment. 
Four of these 9 events were within the first 6 months of treatment. The overall 2-year cumulative 
incidence of a recurrent venous thrombosis was 8% (95% CI 4 to12). The incidence rate was 
43.2 per 1000 person-years (95% CI 27.8 to 58.7 per 1000 person-years), ie, >4% recurrence 
risk per year (The Table and Figure 1). The time between first and second events varied from 
45 days to 5.5 years. Of the 30 recurrences, 18 were located only in the upper extremity, 1 in the 
arm in combination with a pulmonary embolism, 6 in the leg, 1 was a Budd-Chiari syndrome, 
and 4 were pulmonary emboli without a known origin. Of the 19 patients with a recurrent 
thrombosis in the arm, 14 thromboses were located in the same arm as the first occurrence, 
but 5 were on the opposite side. Of these 19 patients 8 had a malignancy, compared with 70 
out of all 224 patients. Four of these 8 patients developed a recurrent thrombosis (50%) in the 
same arm as the first event. Of the 22 patients with a recurrent event without malignancy, 10 
(45%) developed the event in the same arm as the first event. 
Of the 224 patients, 31 patients were censored (because of recurrence, death resulting from 
causes other than venous thrombosis or withdrawal from the study) during the initial 6 
months of treatment. Of the remaining 193 patients, 163 discontinued treatment during 
our study (115 within 6 months, 48 after >6 months), and 30 patients were still receiving 
anticoagulant treatment at the end of follow-up. Apart from the overall group of 224 patients, 
13
 Figure 1 Kaplan Meier for risk of recurrent event in the overall group of 224 patients 
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we also report the results of these 163 patients after their discontinuation of treatment. 
Of the 163 patients who discontinuated vitamin K antagonist treatment, 21 subsequently 
had a recurrent event. The median follow-up after discontinuation of vitamin K antagonist 
treatment in these patients was 2 years (range 0 to 7.2 years) (Figure 2). The 2-year 
cumulative incidence was 7% (95% CI 2 to12). The incidence rate after discontinuation was 
40.1 per 1000 person-years (95% CI 23.0 to 57.3). The incidence of recurrence for the 61 
patients who did not discontinue treatment at any time during follow- up (224-163=61, of 
whom 9 had a recurrence) was 122.5 per 1000 person-years 95% CI 42.4 to 202.4. Some of 
these (4 out of 9) were early recurrences, during the first 6 months of treatment; median 
duration of follow-up was 6 months (5th percentile, 1 month; 95th percentile, 75 months).
Risk factors at baseline
The table shows the effects of putative risk factors present at the time of first venous 
thrombosis on the incidence of a recurrent event for the overall group of 224 patients and 
for 163 patients after discontinuation of vitamin K antagonist treatment.
In the overall group female sex (adjusted HR [HRadj] 1.8; 95% CI 0.9 to 3.9), a first 
nonsubclavian vein thrombosis (HRadj, 2.0; 95% CI 0.8 to 2.7) and body mass index (BMI) 
>=25 kg/m2 (BMI 25-29 kg/m2 : HRadj, 1.6; 95% CI 0.7 to 3.8; BMI >=30 kg/m2 : HRadj, 2.7; 
95% CI 1.0 to 7.3) were associated with a higher risk of a recurrent event. A CVC at time 
of first venous thrombosis was associated with a decreased risk of recurrence (HRadj, 0.2; 
95% CI 0.1 to 1.0). The other factors did not show an effect on recurrence risk (the Table). 
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Figure 2 Kaplan Meier for risk of recurrent event in the subgroup of 163 patients after 
discontinuation of vitamin K antagonist treatment 
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The results in 163 patients after discontinuation of vitamin K antagonist treatment did not 
differ from the overall results for most putative risk factors. Only the effect of malignancy 
and oral contraceptive use seemed to be different. Malignancy at time of first thrombosis 
was associated with a weakly elevated risk of a recurrence (HRadj, 1.9; 95% CI 0.7 to 5.3), 
whereas women who used oral contraceptives at time of their first event had a decreased 
risk of a recurrent event (HRadj, 0.5; 95% CI 0.2 to 1.9). Most of these women (32 out of 36 
for whom information about oral contraceptive use after the initial event was available) had 
discontinued oral contraceptives after the initial event. 
Among all 224 patients, 70 were diagnosed with malignancy at or shortly after the time 
of the initial event; 44 of these patients died during follow-up. The overall relative risk of 
recurrence in patients with malignancy was 1.1 (95% CI 0.5-2.4). Of the 47 patients with 
malignancy who discontinued vitamin K antagonist treatment 7 had a recurrent event after 
discontinuation (58.7 per 1000 person-years; 95% CI 15.2 to 102.3). Fourteen recurrences 
occurred in the 116 patients without malignancy (34.6 per 1000 person-years; 95% CI 16.5 
to 52.8). Of the 61 patients who were treated with anticoagulants throughout follow-up, 23 
had a malignancy. Of these 23 patients, 1 developed a recurrent venous thrombosis during 
vitamin K antagonist treatment (30.6 per 1000 person-years; 95% CI 0 to 122).
Coagulation Factors
A blood sample was drawn from 67 patients after they had stopped using vitamin K antagonists. 
Of these 67 patients, 10 experienced a recurrent event. HRs were calculated for elevated levels 
of factor IX and factor XI. Of 6 patients with elevated factor IX levels, 1 patient had a recurrent 
event, compared with 9 out of 61 patients with normal factor IX, which suggests a 2-fold 
increased risk (HRadj, 2.1; 95% CI 0.2 to 23.0). Of 6 patients with elevated factor XI levels, 
1 patient had a recurrent event, compared with 9 out of 61 patients with normal FXI activity, 
again suggesting an elevated risk (HRadj, 3.3: 95% CI 0.4 to 30.5), although in both instances 
with a wide CI. None of the patients with high levels of factor II, factor VII, factor VIII, factor 
X, von Willebrand factor, and fibrinogen experienced a recurrent event. 
Mortality
Fifty-five out of 224 patients (25%) died during follow-up, 34 of whom were women. Twenty 
five of these 55 patients died during the first year. Median age at death was 58 years (5th 
percentile 37 years, 95th percentile 69 years). Malignancy was the main cause of death. 
Forty-four out of 55 patients died of malignancy, of whom 26 were women, ie, of the 70 
patients with a malignancy, 63% (44/70) had died at the end of follow-up. In comparison, 
among the 154 patients without malignancy, 11 patients (7%) had died. Other causes of 
death were the recurrent event itself (n=2), or death related to autoimmune diseases (n=2), 
pulmonary diseases (n=4) and heart failure (n=3).
The risk of death compared to the general population, expressed as an SMR was 5.4-fold 
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male population and 15.5 (95% CI 11.1-21.6) for women compared to the female population. 
When patients with malignancy were excluded, the overall SMR was 1.1 (95% CI, 0.6 to 2.2); 
SMR was 0.5 (95% CI, 0.1 to 3.4) for men and 4.7 (95% CI, 2.3 to 9.9) for women.
Risk Factors Shortly Before a Recurrent Venous Thrombosis
Of the initial 224 patients, 72 were not able to fill in the questionnaire, 55 died, 2 emigrated, 
and 15 refused to participate in further follow-up. Of the remaining 152 patients, 126 
patients returned the inquiry form, and 104 patients answered additional questions by 
mail, Internet or phone. Of these 104 patients, 13 were still using vitamin K antagonist 
treatment and were therefore excluded. Of 91 patients, 12 had a recurrent event. Four 
had a malignancy, 2 had surgery and 3 patients either carried the Factor V Leiden or the 
Prothrombin 20210A mutation, 1 event was related to pregnancy and 2 were idiopathic.
Discussion
We studied the risk of recurrent thrombosis and death in a large cohort of 224 patients with 
a first venous thrombosis of the upper extremity. The cumulative incidence of recurrence 
after 2 years was 8% (95% CI, 4 to 12%), and the incidence rate of recurrence was 43.2 
per 1000 person-years (95% CI, 27.8 to 58.7). Women had a 2-fold higher recurrence risk 
than men and appeared to have, contrary to men, a decreased survival in the absence of 
malignancy. There appeared to be an increased risk of recurrence for patients with a first 
nonsubclavian vein thrombosis and for patients with a BMI >= 25kg/m2. Patients with a 
first thrombosis resulting from a CVC had a decreased risk of a recurrent event. 
After discontinuation of treatment (n=163) the 2 year cumulative incidence was similar at 
7% (95% CI, 2 to 12%), which was also similar to incidences found in 2 previous smaller 
studies (4.2% and 7%) that included only patients after discontinuation of treatment90,108. 
The incidence of recurrence in patients who did not discontinue treatment during our study 
was high (122.5 per 1000 person-years; 95% CI, 42.4 to 202.4). This result is difficult to 
interpret, for, firstly, this figure includes patients with early recurrences (during the first 6 
months of treatment) and patients with end stage disease or a malignancy.   
In one respect, our results are strikingly different from results of previous studies focusing 
on recurrence after a venous thrombosis of the leg. Men with a venous thrombosis of the 
leg clearly have a higher risk of recurrence than women24,30,36,126,127. In contrast, in venous 
thrombosis of the arm we found an increased risk of recurrence for women. There is no clear 
explanation for the gender difference in patients with a venous thrombosis of the upper 
extremity. We found a reduced recurrence risk for women who used oral contraceptives at 
the time of their first thrombosis. However, most women discontinued oral contraceptive 
use after the initial event. Therefore, oral contraceptive use does not explain the difference 
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The incidence rate of recurrence appeared to increase with BMI, whereas BMI was not a 
clear risk factor for a first thrombotic event in the arm86,92,128. First events in the subclavian 
vein tended to recur less often than thromboses in other veins of the arm. The reason may be 
the removal of the CVC in these patients because most CVCs are located in the subclavian 
vein. However, we do not have data about removal of CVCs and therefore we are not able to 
corroborate this explanation. Patients with malignancy appeared to have an increased risk of 
a recurrent event after treatment and prolonged treatment in these patients may be beneficial.
Only 14 of the 30 recurrences were in the same arm as the initial thrombosis. When we 
exclude the 4 pulmonary emboli with unidentified origin, we find that at least 12 recurrences, 
roughly half, occurred in another location. There were no differences in malignancy and 
prothrombotic defects between the patients with a recurrence in the same location and 
patients with a recurrent event in another location.
Nine of the 30 recurrence occurred during treatment. Four of these events were within 6 
months after the first event; therefore, it is uncertain if they are true recurrence or extensions 
of the original clot. Only 1 of these 4 recurrences was in a different extremity. It should be 
noted that the results of the overall group did not differ from the results of the subgroup of 
163 patients after discontinuation of treatment.   
A thrombosis of the arm is associated with a poor prognosis: 25 % (55 of 224) patients died, and 
25 of these deaths were in the first year after thrombosis. These were mainly patients with cancer.
The factor V Leiden and prothrombin 20210A mutation, present in 17% of patients, did 
not affect recurrence risk. This finding is in line with previous studies on recurrence risk 
after a first venous thrombosis of the leg22,23,36. An analysis regarding levels of coagulation 
factors could be performed in 67 patients. Only a few patients had abnormal levels, and 
most of them did not have a recurrent event. Although our follow-up study on patients with 
a first venous thrombosis of the upper extremity is one of the largest studies performed so 
far, the number of patients with prothrombotic defects was small, and thus CIs were wide. 
Therefore, no firm conclusions can be drawn from these results and clinical strategies of 
testing for prothrombotic abnormalities cannot be recommended. 
We were able to trace all 224 patients indirectly via anticoagulation clinics. One hundred and 
twenty six patients were contacted directly by the inquiry form. We did not have information 
about the exact location of the first venous thrombosis in all patients. Because the inability 
to contact patients and the absence of exact information in discharge letters are not likely to 
be related to location of the thrombus, we do not believe they biased our results. Information 
on risk factors preceding the second event was available for 91 patients who discontinued 
vitamin K antagonist treatment through a follow-up questionnaire. Only 2 of the 12 recurrent 
events in this group were idiopathic, indicating that patients with risk factors may need more 









Patients with a first venous thrombosis of the arm have an increased risk of death compared 
to the general population that is mainly due to malignancy. Eight percent of the patients 
experienced a recurrence within 2 years. Being female, having a BMI >25 kg/m2, and having 
a first nonsubclavian vein thrombosis seem to be the most important risk factors for a 
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Summary
Venous thrombosis is a common disease with a high mortality rate shortly after the event. 
However, details on long term mortality in these patients are lacking. The aim of this study 
was to determine long term mortality in a large cohort of patients with venous thrombosis. 
4947 patients from the Multiple Environmental and Genetic Assessment study of risk 
factors for venous thrombosis (MEGA study) with a first non-fatal venous thrombosis 
or pulmonary embolism and 6154 control subjects without venous thrombosis, aged 18 
to 70 years, were followed up for eight years. Death and causes of death were retrieved 
from the Dutch death registration. Standardized mortality ratios (SMRs) were calculated 
for patients compared with control subjects. Several subgroups were studied as well. 
736 participants (601 patients and 135 controls) died over a follow-up of 56999 person-
years. The overall mortality rate was 22.0 per 1000 person-years (95%CI: 20.3-23.9) for 
patients and 4.5 per 1000 person-years (95%CI: 3.8-5.4) for controls. Patients with venous 
thrombosis had a 4.1-fold (95%CI: 3.8-4.4) increased risk of death compared with controls. 
The risk remained increased up to eight years after the thrombotic event, even when no 
additional comorbidities were present. The highest risk of death was found for patients with 
additional malignancies (SMR 5.8, 95%CI: 5.2-6.4). Main causes of death were diseases 
of the circulatory system, venous thrombosis and malignancies. Main limitation was a 
maximum age of 70 at time of inclusion for the first event. Therefore results cannot be 
generalized to those in the highest age categories. Patients who experienced a first venous 
thrombosis had an increased risk of death, which lasted up to eight years after the event, 
even when no comorbidities were present at time of thrombosis. Future long-term clinical 
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Introduction
Venous thrombosis is a multicausal disease that occurs in 1-3 per 1000 persons per 
year2,3,116. Venous thrombosis is associated with considerable morbidity and mortality. 
About 10-20% of patients develop a recurrence within five years22,24,30 and  up to 50% 
develop post-thrombotic syndrome within several months after the thrombotic event129. 
The mortality rate after venous thrombosis is about 20% within one year3,130. Mortality is 2 
to 4-fold higher for patients with pulmonary embolism, of whom 10-20% die within three 
months after the event, than for patients with a deep vein thrombosis of the leg3,50,131,132. 
Malignancy is the main cause of death, however, when only patients without malignancy 
are followed, 12% die within a year after the thrombosis3,7. Another predictor is the 
underlying cause of the first thrombosis, where those with thrombotic events provoked 
by surgery or trauma have a lower three-year mortality risk than those with idiopathic 
thrombosis3. These figures imply that venous thrombosis has a major impact on survival. 
It is currently unknown whether this poor prognosis is limited to the period shortly after 
the thrombotic event, or persists for extended periods. 
In the present study we determined long term survival in a large cohort of consecutive 
patients with a first venous thrombosis compared with age- and sex matched subjects 
without venous thrombosis, who were all followed for up to eight years. 
Methods
Study population and data collection
We used a cohort consisting of all patients and control subjects from the Multiple 
Environmental and Genetic Assessment of risk factors for venous thrombosis-study 
(MEGA study). Details of the study are described elsewhere7,14. In short, the MEGA study 
was set up as a case-control study including 4965 consecutive patients aged 18 to 70 years 
with a first objectively verified venous thrombosis of the leg or pulmonary embolism and 
6297 control subjects recruited between March 1999 and September 2004.  
Patients were recruited from six anticoagulation clinics in the Netherlands, which exclusively 
monitor out-patient treatment with vitamin K antagonists in well-defined geographical 
regions. Patients were included in the study after a median period of one month (range 
13-64 days) after the diagnosis of thrombosis.
The control group consisted of partners of patients (n=3297) and a random control group 
matched on age and sex (n=3000), recruited between January 2002 and December 2004 
using random digit dialing. All patients and controls filled in a detailed questionnaire on 
risk factors for venous thrombosis and several comorbidities present at time of venous 
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Vital status was ascertained through community registries, where all inhabitants are 
registered. Causes of death were obtained from the Central Bureau of Statistics Netherlands, 
the national repository for death certificates. Both primary and secondary causes of deaths 
were retrieved. Causes of death were coded according to the ICD-10 classification125,133. 
In the current study an additional control group was used. We compared cause-specific 
death rates of the patients to those of the general Dutch population, which due to its size 
of the reference group allowed analyses of cause-specific death rates, for which the control 
group of the MEGA study was too small.
Follow-up and Statistical analysis
The observation time was from 30 days after the venous thrombosis, or a similar date in the 
thrombosis-free cohort, to either death, end-of-follow-up (between February 2007 and May 
2009), emigration (n=164, 1.5%), or loss-to-follow-up (n=173, 1.5%), whichever occurred first.
For 152 individuals (1.4%, 9 patients) follow-up was less than 30 days, and they were 
excluded. Censoring due to emigration concerned 164 individuals (1.5%) and to loss-to 
follow-up 173 individuals (1.5%). This implies that follow-up was complete for 97 percent 
of the cohort. Vital status was obtained from the community registries and date of retrieving 
vital status was used as end date of follow-up, if patients were still alive. It was not possible to 
retrieve all vital statuses at the same date. Therefore, the end-date of follow-up lies between 
February 2007 and May 2009.
The cohort of thrombosis-free individuals has a mortality that was exactly equal to the 
general population (SMR 1.0, CI95 0.9-1.2), and there were no differences in mortality 
within the thrombosis-free cohort, between those who were recruited as partners of 
thrombosis patients or by random digit dialing. 
Cumulative incidences and mortality rates were calculated at 1, 5, and 8 years of follow-up. 
Survival was estimated and visualized by Kaplan Meier life-tables and survival curves. 
Standardized mortality ratios (SMRs) were calculated to estimate relative rates of all cause 
mortality, e.g. by type of initial thrombosis. The SMR is the ratio of the observed number of 
deaths over the number of deaths expected when the mortality rate in the cohort of patients, 
with its specific age and sex distribution, was the same as that in the reference group. SMRs 
were calculated for the complete cohort of patients and for several subgroups of venous 
thrombosis patients: 1) for patients with active malignancy at time of inclusion or diagnosed 
within six months after thrombosis, 2) for patients with a provoked first thrombosis without 
malignancy, 3) for patients with an idiopathic first thrombosis, and 4) according to type of 
first venous thrombosis (PE or DVT). An idiopathic thrombosis was defined as a thrombosis 
not related to surgery, hospital admission, injury, plaster cast, active malignancy, oral 
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puerperium. SMRs for these categories of patients were calculated with the mortality rates 
of the complete control group as a reference; and also using only the rates of the controls 
belonging to the same category (e.g., patients with a provoked event were compare to controls 
who also had had surgery or plaster cast, etc). This latter analysis was performed to estimate 
the effect of venous thrombosis on survival conditional on other risk factors for thrombosis.
Hazard ratios of death from all causes per year of follow-up were calculated to estimate the 
decrease of mortality over time for the different sub-groups. To calculate the hazard ratios 
per year the hazard of dying in year X was calculated with all persons that survived up to 
year X. If they survived the whole of year X they were censored at the end of that year. 
To calculate the reduction in median life expectancy we used the average life table of the 
birth cohorts of 1935-1965 of the Dutch population to create a population comparable in 
life expectancy to the MEGA study. To estimate the median life expectancy for the non-
malignant patients we multiplied the death rate per year for the Dutch cohort from the 
mean age at time of thrombosis by sex. The median life expectancy is the age at which 
half of a birth cohort of newborns had died. For this calculation we assumed an equal 
distribution of relative mortality after thrombosis in our population. 
The influence of the presence of concurrent disease at the time of thrombosis on mortality was 
assessed by contrasting the patient cohort with the thrombosis-free cohort by Cox regression 
in strata of participants with or without concurrent diseases present. In addition, the annual 
hazard ratios were adjusted for the number of concurrent diseases present at time of thrombosis 
in the Cox model Concurrent diseases were diabetes, lever disease, kidney disease, heart 
failure, rheumatoid arthritis, chronic bronchitis, emphysema, myocardial infarction, stroke or 
hemorrhage of the brain, surgery 3 months prior to thrombosis and multiple sclerosis. 
Hazard ratios were adjusted for sex and age. The assumption of proportionality was tested 
both visually from the Kaplan Meier curve, and statistically, with the proportional hazard 
test provided by the software package used. 
For the analysis of cause-specific mortality SMRs were calculated with the rates from the general 
population as reference. Analyses were performed using STATA 10.1. (Stata Corporation, 
College Station, Texas). This study was approved by the Ethics Committee of the Leiden 
University Medical Center and written informed consent was obtained from all participants. 
Results
Baseline characteristics
4947 patients with a first venous thrombosis and 6154 controls were followed during a total 
period of 27 270 and 29729 person-years, respectively. The baseline characteristics of patients 
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month-9.9 years) for patients and 4.4 years (range 1 month-9.1 years) for controls. 601 (12%) 
patients died and 135 (2%) controls. Median time between inclusion and death was 1.7 years 
(range 36 days-9.2 years) for patients and 2.9 years (range 57 days–8.1 years) for controls. 
Overall mortality
The overall mortality rate after thrombosis was 22.0 per 1000 person-years (CI95: 20.3-23.9), 
and the overall mortality rate for the control subjects was 4.5 per 1000 person-years 
(CI95 3.8-5.4). The figure shows an increased risk of mortality for all patients compared 
with controls and for patients without malignancy compared with control subjects up to 
eight years after the thrombotic event. 
Mortality of patients with malignancy
Patients with venous thrombosis and malignancy had, as expected, the highest risk of 
mortality. Overall, 55% of the patients’ with malignancy and thrombosis died during follow-
up, half of whom during the first year after thrombosis (table 2). Patients with malignancy 
had a 17-fold increased risk of death (SMR 17.5; CI95: 15.8-19.4) compared to the control 
group. Remarkably, when patients with malignancy and thrombosis were compared with 
individuals with malignancy without thrombosis they still had a five times higher rate of 
death (SMR5.8; CI95: 5.2-6.4) (table 3).
Figure 1. Kaplan Meier survival curves for patients and controls 
Year 0 1 2 3 4 5 6 7
N Controls 6154 5954 5830 5159 3553 2420 1447 828
N Controls died 19 27 26 26 14 11 9 3
N Patients 4947 4669 4484 4296 3700 2915 2136 1351
N Patients died 197 121 86 47 49 33 33 35
N Patients without malignancy 4297 4194 4098 3963 3421 2704 1997 1270
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Table 1. Baseline characteristics of the study population
Patients n=4947 % (N) Controls n=6154 % (N)
Sex (% men) 46 % (2271) 46 % (2854)
Mean age at index† (range) 49 (18-70) 47 (18-70)
Median age at index† (range) 50 (18-70) 48 (18-70)
Malignancy* 13 % (619) 4 % (233)
Diabetes 3.7% (183) 3.2% (195)
Liver disease 0.5% (27) 0.3% (20)
Kidney disease 1.2% (59) 0.4% (23)
Myocardial infarction 2.8% (137) 1.8% (113)
Heart failure 1.2% (76) 1.0% (60)
Stroke or hemorrhage of the brain 3.0% (154 ) 1.8% (115)
Chronic bronchitis 5.1% (253) 2.7% (165)
Emphysema 1.3% (66) 0.6% (35)
Multiple Sclerosis 0.5% (30) 0.3% (17)
Rheumatoid arthritis 3.0% (144) 2.1% (132)
*Malignancy at time of or within 6 months after the index date types of cancer have been previously 
reported (12).
†Index date was date of thrombosis for patients and date of participation in the study for control subjects.
Mortality rates for patients without malignancy
Patients with venous thrombosis without malignancy had an overall 2-fold increased risk 
of mortality compared to the control group (table 3). The risk was comparable for patients 
with different forms of thrombosis (DVT vs PE) and for patients with a provoked or an 
idiopathic thrombosis.
Table 2 Cumulative incidences of mortality for different subgroups and controls overall, during the 1st 
year and during the first 5 years of follow-up.
*N at risk
1 year 5 years Overall (8 years)
N§ Cum Inc (95%CI) † N§ Cum Inc (95%CI) † N§ Cum Inc (95%CI) †
Patients 4947 197 4.0% (3.4-4.5) 500 10.1% (9.3-10.9) 601 12.1% (11.6-13.4)
Malignancy + 650 165 25.4% (22.0-28.7) 332 51.1% (47.2-54.9) 358 55.1% (51.3-58.9)
Malignancy - 4297 32 0.7% (0.5-1.0) 168 3.9% (3.3-4.5) 243 5.7% (5.0-6.3)
Provoked 2949 21 0.7% (0.4-1.0) 94 3.2% (2.6-3.8) 122 4.1% (3.4-4.9)
Idiopathic 1348 11 0.8% (0.3-1.3) 74 5.5% (4.3-6.7) 121 9.0% (7.5-10.5)
Controls 6154 19 0.3% (0.2-0.4) 112 1.8% (1.5-2.2) 135 2.2% (1.8-2.6)
*N=number, †Cumulative incidence with 95% confidence interval, § Number of deaths, װ Individuals with 
malignancy excluded $Idiopathic venous thrombosis were those without malignancy, surgery, hospital 
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Table 4 shows the hazard ratios year by year during follow-up. The relative risk of death was 
highest during the first three years, in all groups. Overall, patients with thrombosis had a 
persistent elevation in the risk of death, except for those with transient provoking factors; in 
this group the risk became, over time, similar to that of subjects who had provoking factors at 
baseline but did not suffer thrombosis. In contrast, for those who suffered idiopathic thrombosis, 
the risk of death remained over two-fold increased up to eight years after the thrombosis. 
The reduction of median life expectancy for those without malignancy was five years for 
men and women. The estimated median life expectancy was 76 for men and 79 for women 
compared to 81 and 84 years respectively for the Dutch population. 
Comorbidity
Patients with thrombosis and without malignancy have an increased risk of death which could 
be explained by concurrent other major disorders (table 4). When we stratified our study 
population for those with and without concurrent disorders we found no difference in risk of 
death in the stratum of participants with comorbidities (HR 1.4 (1.0-2.0) for patients with venous 
thrombosis compared to controls). However, for patients without concurrent major disorders at 
time of thrombosis overall a HR of 2.5 (95CI: 1.9-3.4) was found compared to controls without 
concurrent disorders and thrombosis. The increased risk of death among patients with venous 
thrombosis can therefore not fully be explained by the presence of these concurrent disorders. 
Causes of death
The main primary cause of death was malignancy (n=392, 65%) followed by diseases of the 
circulatory (n=80, 13%) and respiratory (n=34, 6%) system (table 6). Twenty-four patients 
died of pulmonary embolism (which is classified under circulatory) either as primary cause 
(n=7) or as a complication (n=17). 
Table 3. Standardized mortality ratios (SMR)  
N patients (events) SMR overall (95% CI)* SMR specific (95% CI)†
Overall 4947 (601) 4.1 (3.8-4.4) 4.1 (3.8-4.4)
Malignancy + 650 (358) 17.5 (15.8-19.4) 5.8 (5.2-6.4)
Malignancy - 4297 (243) 1.9 (1.7-2.2) 2.2 (2.0-2.5)
    DVT# 2505 (144) 2.0 (1.7-2.3) 2.3 (2.0-2.7)
    PE# 1257 (72) 2.0 (1.6-2.5) 2.3 (1.8-2.8)
    DVT + PE# 535 (27) 1.4 (0.9-2.1) 1.6 (1.0-2.5)
    Provoked‡ 2949 (122) 2.0 (1.6-2.3) 2.4 (2.0-2.9)
    Idiopathic$ 1348 (121) 1.9 (1.6-2.3) 2.1 (1.8-2.5)
*SMRs are calculated with the non-thrombosis cohort as a reference, †SMRs are calculated with the controls 
with the same selection criteria as the patients as a reference, ‡ Individuals with malignancy excluded # 
DVT are patients with a first venous thrombosis of the leg without malignancies, PE are patients with a first 
pulmonary embolism without a diagnosis of a DVT without malignancies, DVT+PE are patients diagnosed 
with both PE and DVT without malignancies. $Idiopathic venous thrombosis were those without malignancy, 
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Cause-specific mortality was compared with data from the general population. Patients had 
two times higher rates of deaths from diseases of the circulatory system (n=80, SMR 2.2, CI95: 
1.8-2.7) and three-times higher death rates of diseases from the respiratory system (n=34, SMR 
3.3, CI95: 2.4-4.7) than the general population. Venous thrombosis and malignancy were the 
causes of death with the highest SMR compared to the general population (table 5). Patients 
who died of diseases of the respiratory system mainly died of chronic obstructive pulmonary 
diseases or pneumonia as primary cause of death. Five patients died of either a subarachnoid or 
intracerebral hemorrhage of whom three were on anticoagulation treatment at time of death.
For patients without malignancy the main causes of death were diseases of the respiratory 
system and diseases of the circulatory system (SMR 3.4, CI95: 2.3-4.9 and 2.3, CI95: 1.8-2.9, 
respectively). Compared with the general population they did not have an increased risk of 
death due to malignancies (table 5).  
Discussion 
We studied long term mortality after a first venous thrombosis in 4947 patients followed for 
a median period of 5.5 years, compared with a thrombosis-free cohort of 6154 individuals. 
The overall mortality rates were 22.0 per 1000 person-years for all patients. Overall, the death 
rate in patients was 4.0-fold increased and in those without a malignancy over two-fold 
increased. In all patients except those with a transient provoking risk factor underlying the 
initial event, death rates remained elevated up to eight years after the thrombotic event. 
Not many studies have studied the long term risk of mortality after venous thrombosis. In a 
previous study from Norway, the cumulative incidences at one year were much higher than 
Table 5. Increased mortality per cause of death compared with the Dutch population











I00-I99 Diseases of the circulatory system 80 (13) 2.2 (1.8-2.7) 72 (30) 2.3 (1.8-2.9)
I21 Acute myocardial infarction 26 (4) 2.6 (1.8-3.8) 23 (10) 2.7 (1.8-4.0)
I61 Cerebral Hemorrhage 4 (0.6) 1.9 (0.7-5.0) 2 (1) 1.1 (0.3-4.4)
I63 Cerebral infarction 1 (0.1) 0.7 (0.1-5.1) 1 (0.5) 0.8 (0.1-6.0)
I64 Stroke 2 (0.3) 0.9 (0.2-3.6) 2 (1) 1.1 (0.3-4.3)
I26 & I80 Venous thromboembolism 7 (1) 3.9 (1.9-8.3) 7 (3) 4.2 (2.0-8.8)
C00-C99 Neoplasms 392 (65) 5.1 (4.7-5.7) 69 (29) 1.1 (0.8-1.3)
J00-J99 Diseases of the respiratory system 34 (6) 3.3 (2.4-4.7) 29 (12) 3.4 (2.3-4.9)
J44 Chronic obstructive pulmonary disease 19 (3) 3.6 (2.3-5.7) 16 (7) 3.6 (2.2-5.9)
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those we found. In the Norwegian study a cumulative incidence at one year of 14.5% was 
found for cases with an idiopathic venous thrombosis, of 9.7% for provoked cases, and of 
63.4% for cancer patients, while we found cumulative incidences of 0.8%, 0.7% and 25.4% 
respectively3. These differences result from the inclusion of inpatients in the Norwegian study, 
thereby also counting early deaths, and the inclusion of patients of all ages, while our study 
was restricted to patients younger than 70 at the time of the first event. This implies that 
overall mortality in patients with venous thrombosis is even higher than we report. Because of 
our extended follow-up for up to eight years after the thrombotic event, our most important 
observation is that increased mortality for thrombosis patients persists for a prolonged time. 
Furthermore, we showed that, when only the long term survival is taken into account, there 
is no longer a difference in survival for patients with a DVT and PE. This indicates that the 
highly increased risk of death for those with pulmonary embolism is mainly present during 
the first month after venous thrombosis. Recently, an Austrian study did not find an increased 
risk of long-term mortality for patients with venous thrombosis134. However, they included 
patients at a median time of 14 months after thrombosis up to 6 years after the thrombotic 
event. Due to this delayed inclusion only long-term survivors of thrombosis were included in 
the Austrian study and therefore no increase in mortality was found.
We confirmed previous observations that patients with malignancy and venous thrombosis 
have a very poor prognosis, substantially worse than patients with cancer without 
thrombosis, with a 5.8-fold difference in our study135,136. Although death from recurrent 
thrombosis was clearly elevated after a first thrombotic event, most patients died of other 
causes, mainly of the circulatory system. While one is tempted to explain this by pre-existing 
comorbid conditions, death rates were also persistently elevated after idiopathic thrombosis 
and in those without any major illnesses. 
Main causes of death, apart from malignancies, were diseases of the circulatory and 
respiratory system. These results are in line with previous studies which described 
associations between risk factors for venous and arterial thrombosis as well as an increased 
risk of arterial thrombosis for those who experienced venous thrombosis137–139. Alternatively, 
misclassification of cause of death may explain (part of) the results, especially when no 
further research into the cause of death was performed, although one would expect this 
to affect the results in the opposite direction (patients with previous pulmonary embolism 
may be more readily misclassified as having died of pulmonary embolism than of other 
lung diseases than those without a history of pulmonary embolism).   
Our study may have suffered from some limitations: as discussed above causes of death were 
not objectively verified. However misclassification by the physician determining the cause 
of death is most likely to have been equal in this population and in the general population, 
which would have led to an underestimation of the risks we have found. Furthermore, we 
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underestimated. Moreover, our results cannot be extrapolated to patients older than 70 
years at the time of thrombosis, or to children.  
Among the major strengths of this study are the large size of the cohort, and the long 
follow-up period.  Mortality data was retrieved from the national registry where 98.5% 
of participants were found. Therefore, loss to follow-up was minimal and dates of death 
were accurate. This was the first study that calculated mortality rates compared with the 
general population and compared to specific control groups. Therefore, we were able to 
define overall risks of death up to eight years after thrombosis as well as the risk for several 
subgroups. Our results underline the major consequences of venous thrombosis, not only 
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Previous studies have suggested an increased risk of pulmonary embolism in patients with 
acute exacerbations of chronic obstructive pulmonary disease (COPD) but not of deep 
venous thrombosis. The aim of this study was to assess the risk of deep venous thrombosis 
and pulmonary embolism conferred by COPD in a large case-control study on risk factors 
for venous thrombosis (MEGA study). 3897 patients with venous thrombosis and 5752 
controls were included. The presence of COPD before the thrombotic event or index date 
was assessed by questionnaires. Participants were classified as having COPD when they 
reported to have chronic bronchitis or emphysema and were using medication for these 
disorders. COPD was reported by 186 patients (4.8%) and 132 controls (2.2%). COPD was 
associated with a 3.2-fold (CI95 2.4-4.2) and a 1.6-fold (CI95 1.2-2.1) increase in risk of 
pulmonary embolism and deep venous thrombosis respectively. For pulmonary embolism 
relative risks increased with severity of COPD to an odds ratio of 4.6 (CI95 4.1-5.1) but 
for deep venous thrombosis they increased only minimally. We postulate 5 possible 
explanations for the differentially increased risk found for pulmonary embolism and deep 
venous thrombosis. In conclusion, COPD is a moderately strong risk factor for pulmonary 










In the 1960s, the first reports on an association between chronic obstructive pulmonary disease 
(COPD) and pulmonary embolism were published1,2. Since then, two case series reported a 
prevalence of around 20% for a history of pulmonary embolism (PE) among patients with 
COPD, which is much higher than the prevalence of a history of pulmonary embolism in the 
general population (incidence 0.4 per 1000 per year)3,4. More recently, Schneider et al. reported 
from the UK General Practitioners Research Database (GPRD) a 2.5-fold increased risk of 
pulmonary embolism in patients with mild COPD and a 7.5-fold increased risk for patients 
with severe COPD compared with patients without COPD5. Results for venous thrombosis of 
the leg were inconclusive with relative risks of 1.37 for mild COPD and 0.79 for severe COPD. 
These results concerned a relatively small nested case-control study in a cohort of COPD and 
non-COPD patients with 136 patients with PE and 210 with DVT. Schneider et al argued that 
the difference in relative risks for DVT and PE was possibly due to misclassification of PE in 
COPD patients in the absence of a true association.
In the MEGA study we previously reported increased mortality (3.7-fold) due to COPD in 
patients with venous thrombosis compared with the general population6. In another report 
from the same study investigating risk factors for venous thrombosis, an 8-fold increase in 
risk of pulmonary embolism was found for individuals with recent pneumonia while the risk 
of DVT was only 3-fold increased compared with individuals without pneumonia7,8. These 
data indicate an association between inflammatory lung diseases and venous thrombosis, 
and, moreover, an association that is mainly if not exclusively present for PE and not for DVT. 
We studied the association between COPD and venous thrombosis of the leg and pulmonary 
embolism separately in a large case-control study. Furthermore we postulate and critically 
examine several non-causal explanations for the higher risk of pulmonary embolism than 
of deep venous thrombosis of the leg associated with COPD, such as misclassification, 
confounding, bias, or differences in baseline risks of pulmonary embolism and deep venous 
thrombosis of the leg. 
Methods
Ethics statement
This study was approved by the Ethics Committee of the Leiden University Medical Center 
and written informed consent was obtained from all the participants. The investigation has 
been conducted according to the principles expressed in the Declaration of Helsinki.
Study population
The MEGA study is a large population based case-control study into risk factors for 
venous thrombosis, which included 4956 patients with a first venous thrombosis of the 









between March 1999 and September 2004. These clinics exclusively monitor outpatient 
treatment with vitamin K antagonists in a well-defined geographical region. In total 
6297 controls were included, of whom 3000 via random digit dialing and 3297 partners 
of the cases. All patients and controls filled in a detailed questionnaire on risk factors 
for venous thrombosis9,10. The questions also concerned comorbidities, among which 
emphysema and chronic bronchitis; and a list of current medications. For this study, 
COPD was defined as self-reported emphysema or chronic bronchitis in combination 
with medication use for COPD, which was defined as all medication registered for the 
indication COPD in the Netherlands11. Only patients with either a diagnosis of deep 
venous thrombosis of the leg without pulmonary embolism or pulmonary embolism 
without concurrent DVT, confirmed with discharge letters were included for all analysis, 
patients with both PE and DVT were only included in the analysis of COPD as risk factor 
for DVT and or PE. Participants were excluded if the questions about COPD were not 
filled in. In total 447 patients were excluded because they had a combined diagnosis 
of DVT and PE, and 630 patients and 548 controls were excluded because of missing 
data on either medication use or the presence of chronic bronchitis or emphysema. 
Therefore 4281 patients and 5752 controls were included in the analysis (figure 1). While 
chronic bronchitis and emphysema are both classified as COPD, emphysema is generally 
considered as the more severe condition. The risk of chronic bronchitis and emphysema 
was therefore also analyzed separately. Odds ratios and 95% confidence intervals were 
calculated for cases with DVT versus controls and for cases with PE versus controls.









As sensitivity analysis we double-checked the self reported cases of COPD with the Dutch 
hospital admission database. In this database all diagnoses of hospital admissions are 
registered. We linked our patients in two ways; we linked those found by the questionnaires 
to those in the registry and checked how many patients from the MEGA study have been 
admitted for the diagnosis COPD independent of self-reported COPD. For both ways we 
calculated the OR overall and for DVT and PE separately. 
Explanations
We postulate five different explanations for a differential effect on risk of deep venous 
thrombosis of the leg and pulmonary embolism by COPD. These explanations include 
differences due to the scale used to measure the effect, misclassification of either the 
outcome or exposure, confounding and a further exploration of the causal pathway, which 
could be through the use of corticosteroids. All explanations were tested using available 
information from questionnaires and discharge letters.
Putative explanations considered for a differential effect of COPD on PE and DVT:
1. A difference in relative risk is not necessarily a difference in absolute risk
2. Misclassification of diagnosis of COPD as PE
3. Diagnostic suspicion bias
4. Confounding by smoking
5. Medication use (i.e., corticosteroids)
Explanation 1 is related to the difference in the overall risk for pulmonary embolism and 
deep venous thrombosis of the leg. Previous studies showed that the incidence of PE is about 
half that of DVT12,13. The absolute risk (incidence) of venous thrombosis in the presence of 
a risk factor is a function of the incidence in the population without the risk factor and 
the extra risk caused by the risk factor we are interested in (incidence rate difference). The 
incidence for patients without the risk factor is similar to the reported overall incidence 
when the prevalence of the risk factor studied is low, which is the case for COPD.  
One may argue that there is truly a different effect of a risk factor on two diseases, when it 
causes more cases of one disease than the other, i.e., if the incidence rate difference in the 
absence and presence of the risk factor for one disease is greater than for the other. This is 
graphically displayed in figure 2.
To determine whether the differences found were not due to differences in baseline risk for 
PE and DVT, the absolute increase in risk in the presence of COPD should be estimated. 
This was not directly possible in our own study due to the case-control design. Therefore, 
we used population incidence rates reported by Naess et al13. The characteristics of this 
study population from Norway are similar to those of the participants of the MEGA study 
and therefore we expect these baseline incidences to be similar to the baseline incidences in 









Explanation 2 is about misclassification of the diagnoses of COPD and PE. In this scenario 
COPD exacerbations are misclassified as PE. This kind of misclassification will not be 
present for patients with COPD and DVT as the clinical symptoms are obviously different. 
Whether the diagnoses of COPD and PE can be confused depends mainly on the diagnostic 
technique used. Diagnosis by CT-scan will not confuse COPD and PE, while diagnosis 
by VQ-scanning or perfusion-scan may do so14,15. We tried to estimate in two ways to 
what extent COPD exacerbations could have been misclassified as pulmonary embolism. 
First, we checked the methods of diagnoses for PE and stratified the analysis for method 
of diagnosis. Secondly, we used an indirect method. From patients who were initially 
included in the MEGA study with a pulmonary embolism but were later excluded because 
pulmonary embolism was not objectively proven, discharge letters and questionnaires were 
checked for the prevalence of COPD in these patients. If diagnoses were done correctly, one 
would expect a higher prevalence of COPD and other pulmonary diseases among patients 
who were initially suspected of PE in whom PE was subsequently ruled out than in those 
with PE. If the incidence of other pulmonary diseases was lower in the excluded patients, 
this might indicate that misclassification had been present.
Explanation 3 concerns overlap of the diagnoses due to diagnostic suspicion bias. PE 
patients may also have an asymptomatic DVT and vice versa. When patients are diagnosed 
with a pulmonary embolism, an ultrasound to exclude the presence of a DVT is usually not 
made; vice versa, in cases with DVT without symptoms of PE, the presence of PE is generally 
not examined. This could lead to bias when patients with COPD and DVT are more often 
checked for PE than patients with COPD and PE for DVT. While we excluded patients 
who were diagnosed with both PE and DVT, we checked discharge letters to find out how 
Figure 2. Explanation 1: Differences in baseline and additional risks. Difference in RR for two different 
diseases can be explained by a different effect of a risk factor on the two different diseases (diseases A1 
and B1) or by a difference in baseline risk (diseases A2 and B2). Due to the low baseline risk of disease 
A2, the relative risk is much higher for A2 than the relative risk for disease B2, although the additional 









often additional diagnostics were performed in patients with a diagnoses of only DVT or 
PE and whether this differed among patients with deep venous thrombosis of the leg and 
pulmonary embolism and among patients with and without COPD. Discharge letters from 
all patients with venous thrombosis and COPD were checked for additional diagnostics for 
either PE or DVT as well as discharge letters from a random sample of one hundred patients 
without COPD with pulmonary embolism and one hundred patients without COPD with 
deep venous thrombosis of the leg. 
Explanation 4 concerns possible confounding by smoking. Smoking status could be a 
confounder of the relation between COPD and the occurrence of PE or DVT, as smoking is a 
risk factor for both COPD and venous thrombosis16,17. To test whether the effect found could be 
explained by smoking we included smoking with COPD in two logistic models, one with DVT 
and one with PE as endpoint. Smoking was categorized in three groups, never, current and 
previous smokers. Previous smokers were defined as ever smokers who stopped smoking one 
year before they filled in the questionnaire. This to avoid too include participants that stopped 
smoking between their thrombotic event and filling in the questionnaire. Furthermore, to 
examine whether the presence of both COPD and smoking could lead to synergy we also 
stratified patients and controls in 6 groups: current, previous, and non-smokers, with or 
without COPD, and studied the relative risk of DVT or PE in these groups. 
Explanation 5 involves the usage of corticosteroids and in contrast to the explanations 
above is an explanatory mechanism for a causal association. Corticosteroids are used as 
treatment for COPD and are associated with an increased risk of venous thrombosis18. 
Therefore, a higher risk of pulmonary embolism than DVT may be explained by the use 
of such medication, if this would specifically affect risk of PE. Therefore, odds ratios were 
calculated stratified on corticosteroid usage. Information on corticosteroid use was also 
obtained from the medication list in the questionnaire.
Results
Effect of COPD on the risk of DVT and PE
In total, 543 participants reported suffering from chronic bronchitis or emphysema before 
the thrombosis. Of these 543 participants, 340 were using medication for their disease. In 
total, 208 cases and 132 controls reported having COPD before thrombosis or inclusion and 
used medication for it. Thirty-eight percent of COPD patients used fluticasone, 30% used 
salbutamol, 19% salmeterol, and 13% used several other medications. Of the subjects with 
COPD, 156 patients and 104 controls reported chronic bronchitis and 52 patients and 28 
controls emphysema. Patients with COPD had a 1.6-fold increased risk of DVT compared 
with patients without COPD (odds ratio (OR): 1.6; 95%CI, 1.2-2.1), while they had a 3.2-fold 
increased risk of PE compared with patients without COPD (OR: 3.2; 95%CI, 2.4-4.2). This 









PE (OR: 4.6, CI95 4.1-4.5) than patients with chronic bronchitis (OR: 2.6, CI95 2.3-2.9). 
This effect was not seen in patients with DVT (chronic bronchitis OR: 1.5, CI95 1.2-1.8, 
emphysema OR: 1.4 CI95 0.8-2.0) (table 2). Patients with COPD had a variable risk of 
PE and DVT. There was no consistent trend seen overall and for chronic bronchitis and 
emphysema separately compared to those with only DVT or PE (table 2). When we linked 
these patients to the Dutch hospital admission database we found 32 cases and 14 controls 
that were admitted for COPD. With those cases we found an OR of 2.7 (CI95 1.5-5.1) for 
venous thrombosis. When we stratified the results for cases of DVT and PE we found an 
OR of 1.7 (CI95 0.8-3.7) and 4.1 (CI95 2.0-8.6) respectively. When we double-checked and 
looked at all the cases of COPD found in the admission database those found and not found 
by means of our questionnaires we found 74 patients and 29 controls with COPD. With 
these cases an overall OR of 3.1 (CI95 2.0-4.7). For DVT and PE we found an OR of 1.7 
(CI951.0-2.9) and an OR 5.1 (CI95 3.2-8.4) respectively.
Explanation 1: Different baseline risk of PE and DVT
Population rates are 0.3 per 1000 person-years for PE and 0.5 per 1000 person-years for 
deep venous thrombosis of the leg13. With the odds ratios we found this implies that the 
incidence of DVT among COPD patients is 0.8 per 1000 person-years and the incidence 
or PE among COPD patients 1.0 per 1000 (0.5*1.6=0.8 and 0.3*3.2=1.0). Therefore there 
is a larger increase in the incidence of PE than of DVT due to COPD (incidence rate 
difference 0.7 per 1000 person-years for PE (1.0-0.3) and 0.3 per 1000 person-years for 
DVT (0.8-0.5)). When COPD was stratified according to severity (chronic bronchitis versus 
emphysema) the incidence rate of pulmonary embolism (and accordingly, the incidence 
rate difference) clearly increased with severity (0.8 for chronic bronchitis versus 1.4 for 
emphysema per 1000 person-years) while the incidence rate of DVT did not (0.8 versus 0.7 
per 1000 person-years, respectively) (table 2). Therefore, both on an absolute and a relative 
scale COPD increases the risk of PE more than that of DVT.
Table 1. Baseline characteristics of patients and controls
Variable Patients Controls
N 4281 5752
Sex (% men) 45.9% 46.3%
Age (mean) 48.9 47.2
BMI (kg/m2) (mean) 27.8 26.7
Smoking 59.6% 56.1%
Malignancies 13.3% 4.7%
Factor V Leiden 13.7% 4.0%
DVT (N) 2467 -
PE (N) 1412 -










One third of all patients with COPD and PE had been diagnosed by CT-scan (33 of 98), a 
method that cannot lead to confusion of PE and COPD diagnoses. When including only 
patients with PE who were diagnosed by CT scan, the risk of PE in individuals with COPD 
was 3-fold increased compared with individuals without COPD (OR: 3.0; 95%CI 2.0-4.4). 
Similarly, when including only patients with PE who were diagnosed by VQ-scan, the risk 
of PE in individuals with COPD was 3.3-fold increased compared with individuals without 
COPD (OR: 3.3; 95%CI 2.4-4.4). Furthermore, a total of 39 patients were initially included 
in the MEGA study but subsequently excluded because PE was not objectively confirmed. 
Of these patients 13% had COPD compared with 6% among the patients with pulmonary 
embolism in our study. These figures demonstrate that misclassification due to diagnosing 
COPD exacerbations, as PE does not explain the increased risk of PE in COPD patients. 




 yes/no N cases N controls OR (CI95) Incidence rate*
Incidence rate 
difference
DVT Yes 88 132 1.6 (1.2-2.1) 0.8 per 1000
No 2379 5620 1 (ref) 0.5 per 1000 0.3 per 1000
PE Yes 98 132  3.2 (2.4-4.2) 1.0 per 1000
No 1314 5620 1 (ref) 0.3 per 1000 0.7 per 1000
PE+DVT Yes 22 132 2.5 (1.6-3.9) 1.3 per 1000
No 380 5620 1 (ref) 0.5 per 1000 0.8 per 1000
Chronic bronchitis 
 yes/no
DVT Yes 70 104 1.5 (1.2-1.8) 0.8 per 1000
No 2379 6168 1 (ref) 0.5 per 1000 0.3 per 1000
PE Yes 66 104 2.6 (2.3-2.9) 0.8 per 1000
No 1524 6168 1 (ref) 0.3 per 1000 0.5 per 1000
PE+DVT Yes 20 104 3.1 (1.9-5.1) 1.5 per 1000
No 380 6168 1 (ref) 0,5 per 1000 1.0 per 1000
Emphysema 
 yes/no
DVT Yes 18 28 1.4 (0.8-2.0) 0.7 per 1000
No 2379 6168 1 (ref) 0.5 per 1000 0.2 per 1000
PE Yes 32 28 4.6 (4.1-5.1) 1.4 per 1000
No 1524 6168 1 (ref) 0.3 per 1000 1.1 per 1000
PE+DVT Yes 2 28 1.2 (0.3-4.9) 0.6 per 1000
No 380 6168 1 (ref) 0.5 per 1000 0.3 per 1000
*incidence rates are per 1000 person-years
OR=Odds Ratio, ref=reference, CI95=95% confidence interval, DVT=Deep vein thrombosis, PE=pulmonary 









Explanation 3: Diagnostic suspicion bias
Table 3 shows the proportions of subjects in whom diagnostic procedures for both DVT 
and PE were performed for those with and without COPD and pulmonary embolism 
and venous thrombosis of the leg separately. These proportions are about the same in all 
groups. This shows that there is not an excess of PE diagnosed in COPD patients due to 
more intense diagnostic work-up. In addition, for most patients with pulmonary embolism 
discharge letters reported that no symptoms were observed of the leg and vice versa.  
Explanation 4: Confounding by smoking
When we adjusted for smoking the ORs for both DVT and PE did not change, indicating 
that the relation found was not confounded by smoking (table 3). When we looked into 
synergistic effects between COPD and smoking we did not observe any for patients with 
DVT but the effects of smoking and COPD seemed to add up for PE (table 4). 
Explanation 5: Medication
Table 5 shows the stratified analysis for corticosteroids. In both strata the effect of COPD is 
more pronounced for PE than DVT. In COPD patients who did not use steroid drugs the 
risk of PE was 2.9-fold increased (95% CI, 2.1-3.9) compared with those without COPD, 
which is similar to the overall effect. This implies that the differential effect of COPD on PE 
cannot be explained by steroid use.
Table 3. Explanation 3: Additional diagnostics performed in the several groups
Diagnosis Additional diagnostics PE/DVT
DVT – COPD 14% (n=388)
DVT + COPD 11% (n=10)
PE – COPD 17% (n=238)
PE + COPD 13% (n=12)
DVT=deep vein thrombosis, PE=pulmonary embolism, COPD=Chronic obstructive pulmonary disease










COPD 1.6 (1.2-2.10 1.5 (1.2-2.0) 3.2 (2.4-4.1) 3.2 (2.4-4.2)
Smoking
    Current smoker 1.1 (1.0-1.3) 1.1 (1.0-1.3) 0.8 (0.7-0.9) 0.8 (0.7-0.9)
    Previous smoker 1.4 (1.2-1.5) 1.4 (1.2-1.5) 1.8 (1.6-2.0) 1.8 (1.6-2.0)
*Adjusted for smoking or COPD respectively.
OR=Odds Ratio, CI95=95% confidence interval, ORadj=Adjusted Odds ratio, DVT=deep vein thrombosis, 










In this large study we found a threefold increased risk of PE in patients with COPD, which was 
clearly higher than the effect on DVT. Patients with COPD had a 3.2-fold (95% CI, 2.4-4.2) 
increased risk of pulmonary embolism compared with those without COPD while the risk 
of deep venous thrombosis of the leg was only 1.6-fold (95% CI, 1.2-2.1) increased. The 
differential effect was stronger when severity of the COPD was taken into account. None of five 
possible explanations for the difference we proposed were likely to account for the difference. 
The difference was present both on an absolute and relative scale. The absolute risk of PE 
increased with severity of COPD while the incidence of DVT did not (explanation 1). Neither 
could it be explained by misclassification of either the exposure or outcome as there were no 
differences in risks found for those diagnosed with VQ-scanning and CT (explanation 2) or to 
differences in additional diagnostics between those with and without COPD (explanation 3). 
The difference was not caused by smoking habits (explanation 4). Lastly, a causal explanation 
through differences in medication use could be rejected because there were no differences in 
the risks found for those using and not using corticosteroids (explanation 5). 
The results that we describe are similar to the results of Schneider et al5, although more 
pronounced. Schneider et al. found a 2.2-fold increased risk of pulmonary embolism and a 
1.4-fold increased risk of deep venous thrombosis of the leg in individuals with COPD compared 
with individuals without COPD. Schneider et al. split their results for mild, moderate and severe 
COPD. They also saw an increase in the risk of PE with severity of COPD, up to a 7-fold increase 
in risk of PE in severe COPD patients compared with individuals without COPD. 
Table 5. Odds ratios for DVT and PE for different combinations of COPD and smoking
COPD Smoking DVT (OR (CI95)) PE (OR (CI95)
No No 1 (ref) 1 (ref)
Yes No 2.0 (1.3-3.2) 2.8 (1.6-4.8)
No Current 1.1 (1.0-1.3) 0.8 (0.7-0.9)
Yes Current 1.5 (0.9-2.4) 3.3 (2.1-5.2)
No Previous 1.4 (1.2-1.6) 1.8 (1.6-2.1)
Yes Previous 1.9 (1.2-3.0) 5.0 (3.3-7.5)
OR=Odds ratio, CI95=95% confidence interval, ref=reference category, DVT=deep vein thrombosis, PE 
pulmonary embolism, COPD=chronic obstructive pulmonary disease
Table 6. Explanation 5: Stratification corticosteroids
Overall (OR(CI95)) Corticosteroids + (OR(CI95)) Corticosteroids – (OR(CI95))
DVT 1.6 (1.2-2.1) 1.5 (0.9-2.6) 1.6 (1.2-2.2)
PE 3.2 (2.4-4.2) 4.2 (2.6-6.7) 2.9 (2.1-3.9)









Some limitations should be mentioned. Firstly, all our data have been collected by 
questionnaires and discharge letters. Therefore, we may have missed some diagnoses of 
COPD or included cases of chronic asthma that were diagnosed as COPD. However, it is 
likely that this misclassification would be the same in patients with DVT and PE. Therefore 
we performed a sensitivity analysis with the Dutch hospital admission database. Although 
most patients with COPD are not admitted for this indication and those found are therefore 
the most serious cases of COPD we still found comparable ORs overall and DVT and PE 
separately compared to our self-reported data. Furthermore, we did not have data on long 
function. Therefore, the diagnosis emphysema may not have been more severe than chronic 
bronchitis in all patients. Thirdly, explanations 2 and 3 cannot be fully excluded in this 
study due to lack of information, as not all information is always mentioned in the discharge 
letters. However, also in this case it is unlikely that this is different for patients with DVT 
or PE. When we studied the risk of DVT and PE in patients with COPD there was no clear 
trend toward either those with only DVT or PE, which could indicate a possible mechanism 
between COPD and venous thrombosis. However there were only 22 cases with COPD and 
both PE and DVT. It is therefore difficult to draw conclusions from this group. 
When we dismiss the alternative explanations for our findings, we may speculate on other, 
more causal explanations. Possibly, COPD plays a role in a local development of pulmonary 
thrombi rather than that they invariably arise from embolization from the leg. A similar 
differential risk between pulmonary embolism and DVT has been shown in patients with 
other pulmonary inflammatory diseases such as pneumonia and chronic asthma7,8,19 These 
consistent results of associations between pulmonary inflammatory diseases and pulmonary 
thrombi make a local development of these thrombi a possibility worth considering. In 
asthma patients, due to the chronic inflammation in the lungs, the production of fibrin in 
the lungs is up-regulated and levels of protein C are downregulated8,20. This may lead to a 
local prothrombotic state. These shifts in fibrin production and protein C levels initiated by 
local inflammation in the lungs due to asthma could also play a role in patients with chronic 
bronchitis, emphysema and pneumonia. The role of smoking should also be considered 
in the causal mechanism, as smoking has been described as a mild risk factor for venous 
thrombosis as well16,17. However, the effect estimated for both COPD and smoking did not 
change in the multivariate model. This indicates that smoking is not a confounder in the 
relation between COPD and DVT or PE. It also indicates that COPD is not on the causal 
pathway between smoking and DVT or PE, i.e. that the presence of this condition does not 
explain the relation that has been described between smoking and risk of VT.  
In conclusion, we found a threefold increased risk of pulmonary embolism for patients with 
COPD, which was substantially higher than that of deep venous thrombosis of the leg. This was 
strongest for those with severe COPD who had a 4.6-fold increased risk. This finding may be a 
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Incidence of recurrent venous throm
bosis
Summary
The reported incidence of recurrent venous thrombosis (VT) varies widely between 12-30% 
within 5 years after the first event. The risk profile for recurrence is different from that for a 
first event, for example with respect to the influence of age and sex. The aim of this study was 
to estimate the incidence of a recurrent event, its location as well as the effect of age and sex 
in a large cohort of patients with a first VT. We followed 4731 patients who were diagnosed 
with a first VT between 1999 and 2004 (MEGA study) until 2008-2009. Recurrences were 
adjudicated from self-reported information in questionnaires, from anticoagulation clinics 
and discharge letters. We designed a decision rule to define for each patient if they had 
a recurrence according to the available information. We calculated incidence rates of 
recurrence and hazard ratios (HR) to estimate the effect of various factors on a recurrent 
event. 673 out of 4731 patients had a recurrent event. 219 additional patients in whom the 
diagnosis was uncertain were censored at the time of possible recurrence. 4731 patients 
were followed during a period of 24 124 person-years (py) (mean 5 years). The overall 
incidence of recurrence was 27.9 per 1000py (95%CI 25.8-30.0). The cumulative incidence 
at 5 years was 11.3%. Men had a 2.2-fold (95% CI 1.9-2.6) higher risk of a recurrent event 
than women. Age was not associated with an increased risk of recurrence (HR 1.0, 95%CI 
1.0-1.0 per year increase in age). Patients with anticoagulation treatment for less than 3 
months were at higher risk of recurrence than patients with treatment for more than 3 
months. Patients with pulmonary embolism (PE) were more likely to have a PE as recurrent 
event than patients with DVT (HR 1.9 95%CI 1.4-2.8) and patients with thrombosis of the 
leg (DVT) were more likely to have a DVT as recurrent event (HR 1.5 95%CI 1.1-1.9) than 
patients with PE. In conclusion, this large study provides precise estimates of recurrence 
risk, which is substantial at about 3% per year, but less than found in some other studies. 
Men are more likely to have a recurrent event and age has no effect. The manifestation (PE 
or DVT) of recurrence is often the same as that of the first event.
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Introduction
Venous thrombosis is a multicausal disease that occurs in 1-3 per 1000 persons per year2,3. It 
is associated with substantial mortality and morbidity including recurrence. The cumulative 
incidence of recurrent venous thrombosis is much higher than that of a first event and varies 
between studies from 4-11% within the first year to 12-30% in the five years after the first 
event21,33,36,38,155.  Incidence rates of recurrence also vary between studies, from 25 to 46 per 
1000 person-years36,38. Sources of this variation include definition of recurrence, setting and 
size of the study (clinical setting versus research setting) and starting point of follow-up. 
In contrast to a first event, only a few risk factors are known to be associated with risk of 
recurrent thrombosis, such as male sex, the presence of a malignancy, and an idiopathic first 
venous event21,36,38,156–162. Age, which is the strongest risk factor for a first venous thrombosis 
does not, or only slightly, increase the risk of a recurrent event36,157–161. However, the separate 
effects of age, male sex and an idiopathic first venous thrombosis are not well established, 
mainly as a result of small sample sizes of the studies reported so far, different cut off points 
for age and different definitions for idiopathic venous thrombosis.
The best way to prevent recurrence is by anticoagulant treatment. However, this has the 
obvious drawback of a major bleeding risk, which is not outweighed by the prevention 
of thrombosis. Therefore, duration of anticoagulant treatment is limited, and the optimal 
duration is not well known, despite several trials into this issue22,26,30,127. 
A recent study showed that recurrent events do not occur at random sites163. To be able to 
predict the location of recurrence may influence the duration of treatment especially when 
a recurrent pulmonary embolism is more likely than a deep venous thrombosis of the leg. 
To address all the issues mentioned above, we performed a large follow-up study of 
almost 5000 patients with a first venous thrombosis. In this study we estimated the risk of 
recurrence, the separate associations of age, sex and an idiopathic first thrombosis with the 
risk of a recurrent event, the effect of different durations of anticoagulation and the relation 
between site of first and recurrent events. 
Methods
Study population
Patients were included from the MEGA study7,14, a large population based case-control 
study into risk factors for a first venous thrombosis, which included consecutive patients 
at six anticoagulation clinics in the Netherlands between March 1999 and September 2004. 
In total 5182 cases and 6297 controls were included in the MEGA case-control study. From 
these cases, patients with a deep venous thrombosis of the leg, pulmonary embolism or 
both were included and patients with a venous thrombosis of the upper extremity were 
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excluded from follow-up. A total of 4956 cases were eligible for the follow-up study. Of 
these cases 225 indicated that they did not want to participate in a follow-up study and were 
therefore excluded (figure 1) leaving 4731 patients for the follow-up study. This study was 
approved by the Medial Ethics Committee of the Leiden University Medical Center and all 
participants gave written informed consent.
Information about recurrences was retrieved in two ways, i.e., from the patients themselves 
via a short questionnaire and from the anticoagulation clinics, which monitor all outpatients’ 
anticoagulant treatment with vitamin K antagonists. The short questionnaire consisted of 
two main questions: 1) “Did you have a recurrent event?” and 2) “In which hospital or by 
which doctor was it diagnosed?”. Questionnaires were sent by mail between June 2008 and 
July 2009. When questionnaires were not returned, the questions were asked by telephone 
interview. During the same period information on possible recurrences of all patients was 
obtained from the anticoagulation clinic where they were initially included for their first 
event and, in case they moved house, at the clinic near their new address. Information on 
the duration of anticoagulant treatment was also obtained from the anticoagulation clinics. 
For all potential recurrences found by the questionnaire, anticoagulation clinic or both, 
discharge letters were requested from the clinician who diagnosed the recurrence according 
to the patient and/or the clinic.





















4956 eligible patients with DVT 
and/or PE in MEGA study 
Exclusion  
- 225 indicated no follow-up questionnaire in 
MEGA study  
4731 patients included in 
follow-up study 
Lost to follow-up N=1002 (21%) (last date known 
to be recurrence free) 
- 99 died 
- 3 emigrated 
- 489 at anticoagulation clinic 
- 411 at MEGA interview
Data sources possible recurrence 
- 3424 questionnaire (endpoint FU) (72%) 
- 1088 anticoagulation clinic (23%) 
- 40 death of possible recurrence (1%) 
- 146 possible recurrences at MEGA (3%) 
- 660 a discharge letter of possible 
recurrence (14%) 
 
- 3757 ≥1 source data source completed 
Endpoint (79%) 
- 892 recurrence (certain/uncertain) 
- 2837 end of study (questionnaire)
Figure 1. Flowchart of follow-up.
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Definition of recurrence
A decision rule regarding certainty of the diagnosis was made according to the information 
collected per patient. The reported recurrences were classified into certain recurrences and 
uncertain recurrences. In this study only certain recurrences were used as endpoint and 
patients with an uncertain recurrence were censored at time of their uncertain recurrence, 
since they were definitely recurrence-free until that time.
To be classified as a certain recurrence, a reported recurrence should fulfil one of the 
following three criteria. 
1. A discharge letter was present concluding a diagnosis of recurrence, based on the 
available clinical and radiological data. This recurrence should be in a different vein or 
in a different part of the body than the first event. The discharge letter had to contain 
information about instrumental diagnostic procedures. If the location of either the first 
or second thrombosis was unclear, an event was still classified as a certain recurrence if 
at least three months had passed since the first thrombosis. 
2. A discharge letter was not available (for example when the treating physician was 
unknown) but information from both the anticoagulation clinic and the patient 
reported a recurrence at a clearly different location than the first event (contralateral 
leg, or DVT after PE or vice versa) or a time period of more than a year had passed 
between the two events (figure 2).
3. A registered cause of death from pulmonary embolism or venous thrombosis at least six 
months after the first event. 
Uncertain recurrences were defined by four criteria, one of which had to apply: 
1. A diagnosis of a possible recurrence in the discharge letter, where clinical and 
radiological data could not distinguish between an extension of the first and a new 
thrombotic event. 
2. A discharge letter was not available (for example when the treating physician was 
unknown) but both the patient and the anticoagulation clinic reported a recurrence 
within a year after the first event. 
3. Information was only available from either the patient or the anticoagulation clinic (figure 2).
4. A registered cause of death from pulmonary embolism or venous thrombosis within six 
months after the first event.
Statistical analysis
The end of follow-up was defined as the date of a recurrent event and in the absence of 
a recurrence, the date of filling in the short questionnaire. If a patient did not fill in a 
questionnaire they were censored at the last date we knew them to be recurrence free. This 
could be either the last date we knew patients to be recurrence-free, or the last visit to 
the anticoagulant clinic, date of death or emigration, or the last moment the patient was 
known to be recurrence-free from information of the MEGA case-control study (figure 1). 
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Duration of follow-up was calculated in two ways, i.e, 1) by starting follow-up at the date 
of the first event or 2) by starting follow-up at the date of discontinuation of anticoagulant 
therapy. Both incident rates and cumulative incidences (at one, two and five years) of 
recurrence were calculated from these two starting points. 
In order to find a range of the incidence of recurrence which includes the true incidence of 
recurrence, we calculated, as a sensitivity analysis, incidences of recurrence for all possible 
recurrences combined (certain and uncertain) and separately for certain recurrences with 
both starting points of follow-up (starting from baseline and discontinuation of treatment). 
Additionally we refined our estimation of the incidence of recurrence by a multiple 
imputation analysis in patients with an uncertain recurrence. With the multiple imputation 
analysis the recurrence status of the uncertain recurrences was estimated using information 
on all comorbidities and risk factors present at time of first venous thrombosis162,163. 
Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster cast, 
hormone use (oral contraceptives and hormone replacement therapy), pregnancy all within 
three months before the event, puerperium, and active malignancies at the time of the event. 
Kaplan Meier estimates adjusted for competing risks were estimated for men and women and 
for patients with an idiopathic and provoked first venous thrombosis separately. Incidence rates 
were calculated for men and women and idiopathic and provoked cases separately in different 
age categories to study risk patterns for these three factors (age, sex and idiopathic thrombosis).
Figure 2. Risk of recurrence for idiopathic versus provoked first venous thrombosis stratified for sex.
Duration of follow-up in years
- Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster or 
hormone use (oral contraceptives and hormone replacement therapy), and pregnancy within three 
months before the event, and without active malignancies or puerperium.
- Provoked venous thrombosis was defined as thrombosis due to surgery, plaster of minor injuries, 
oral contraceptive use, hormone replacement therapy use, pregnancy and puerperium.
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For the analysis on risk factors and optimal duration of anticoagulation, only the certain 
recurrences were used and the uncertain recurrences were censored at time of the reported 
recurrence. Hazard ratios were calculated for all potential risk factors, and all hazard ratios were 
adjusted for age and sex when applicable. All hazard ratios were calculated with follow-up time 
starting at time of first venous thrombosis. The effect of male sex was also studied in a restricted 
analysis excluding women who used oral contraceptives or hormone replacement therapy at 
time of the first thrombotic event as well as women who were or had recently been pregnant at 
that time. Age was studied both as a continuous and a categorical variable with age categories 
of 10 years. These effects were studied in the overall group of patients and in patients without 
cancer and life-long anticoagulation treatment. The latter restriction was done to see the effect 
of these risk factors in those without another very strong risk factor of thrombosis (cancer) and 
in those who cannot be treated more than they already were (lifelong treatment).
First and recurrent events were compared for location (lungs or leg). Left versus right-sided 
first and recurrent thrombosis of the leg were analysed. Observed numbers versus expected 
numbers when locations and sides would be random were calculated as well as hazard ratios 
for site of recurrence per site of first thrombosis.
For the analysis on effect of duration of anticoagulation therapy, patients with malignancies 
at time of thrombosis were excluded. Duration of anticoagulation therapy was calculated 
in months. Survival curves were made for patients who used anticoagulation therapy for 
1-3 months, 4-6 months, 7-12 months, and more than 12 months. To compare the different 
durations of anticoagulation therapy in groups with a similar indication we made separate 
survival curves for those with an idiopathic first venous thrombosis and for those with a 
provoked venous thrombosis due to surgery, plaster cast or minor injuries. All survival 
curves were adjusted for competing risks due to death.  
Analyses were performed with SPSS v21.0 (Chicago, Ill) and STATA SE 12 (Stata 
Corporation, College Station, Tx) for Windows.
Results
Population
Mean age of the patients at time of first venous thrombosis was 48 years and 54% of the 
patients were women. Mean duration of follow-up was 5.1 years when follow-up started at 
time of venous thrombosis and 5.0 years when follow-up started after discontinuation of 
anticoagulation treatment. Total volumes of follow-up were 24 124 and 20031 patient-years 
respectively. In total 79% of patients (n=3729) had a complete follow-up of whom 2 837 
filled in the questionnaire and 892 were followed until (possible) recurrence. In total 1002 
(21%) patients did not complete follow-up either due to death (n=99) or emigration (n=3) 
without recurrence, or did not reply to further queries after a last visit at the anticoagulation 
clinic (n=489) or at a point later during the follow-up period (n=411) (figure 1). 
83
7
Incidence of recurrent venous throm
bosis
Recurrences
From different sources we obtained information about recurrence status from 3 757 patients. 
A total of 972 possible recurrences were found that needed to be confirmed. From the 
information obtained from clinicians, we concluded that 80 of these were not recurrences 
but were diagnoses of either post-thrombotic syndrome or suspected recurrences that were 
excluded by ultrasound or CT-scan to be a recurrent event. Therefore, 892 recurrent events 
could be further classified. Of these, a total of 673 patients were classified to have a certain 
recurrence. 593 patients fulfilled criterion one for certain recurrence. Fifty-eight patients 
were identified as a certain recurrence with criterion 2 and 22 patients with criterion three. 
219 patients had an uncertain recurrence of which 32 fulfilled criterion 1, 19 criterion 2, 
159 recurrences fulfilled criterion 3, and 9 fulfilled criterion 4.  
Incidence of recurrence
When we let follow-up start at time of the first venous thrombosis, we found an incidence of 
27.9 per 1000 person-years (CI95: 25.8-30.0) when only certain recurrences were taken into 
account. When both certain and uncertain recurrences were counted as recurrent events, as 
a sensitivity analysis, we found an incidence of 37.0 per 1000 person-years (CI95: 34.6-39.4) 
(table 1). These incidence rates corresponded to a 5 years cumulative incidence range of 
11% and 15% respectively. 
Of the 673 certain recurrences, 61 (9%) occurred during anticoagulation therapy 
prescribed after the first thrombotic event, whereas 53 of the 219 uncertain recurrences 
(24%) occurred during treatment. When follow-up was started after discontinuation of 
anticoagulation treatment, the incidence of recurrence was 30.6 per 1000 person-years (CI 
95: 28.1-33.0) when only certain recurrences were taken into account. When both certain 
and uncertain recurrences were taken into account an incidence of 38.8 (CI95: 36.1-41.6) 
per 1000 person-years was found. The corresponding 5 years cumulative incidences were 
13% and 19%. When recurrence status was imputed in the group who had uncertain 
recurrences the incidence of recurrence became 29.4 (CI95 27.4-31.7) per 1000 person-
years when follow-up started at time of first venous thrombosis and 32.0 (CI95: 29.6-34.6) 
when follow-up started after discontinuation of treatment (table 1). 
The recurrence rate was high during the first 1.5 years, i.e. 54 per 1000 (CI95: 45-65) 
person-years at 1 year and 42 per 1000 (CI95: 33-52) person-years at 1.5 years, but 
gradually decreased to 25 per 1000 (CI95: 18-34) person-years after 4 years. After this time 
the incidence of recurrence remained stable at 25 per 1000 person-years. 
Risk factors 
Table 2 shows the incidences of recurrence stratified by age, sex, and whether the first 
venous thrombosis was idiopathic or not. Incidences were in all instances higher for men 
than for women. No clear effect of age was seen in any of the categories. 
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Men had a 2.2-fold (95% CI; 1.9-2.6) increased risk of a recurrent event compared with women 
after adjustment for age (figure 3, table 3). After exclusion of women who used oral contraceptives, 
hormone replacement therapy, or were pregnant at time of first venous thrombosis the relative 
risk increased to a 2.8-fold (95% CI; 2.2-3.6) increased risk in men (table 3). 
Age at time of first venous thrombosis was not associated with an increased risk of 
recurrence (table 3). When age was divided in 10-year categories the risk of recurrence was 
still similar in all groups (table 3). 
Patients with a first idiopathic venous thrombosis had a 2.0-fold (95% CI; 1.7-2.3) increased 
risk of recurrence compared with patients with a provoked first venous thrombosis. 
However, after adjustment for sex this relative risk diminished to 1.4 (95% CI; 1.2-1.7). An 
increased risk of recurrent thrombosis after an idiopathic first event was mainly present 
in men (figure 2). Exclusion of patients with cancer and life-long treatment did not lead 
to more than trivial changes in the effects of age, sex, and idiopathic vs. provoked first 
thrombosis (table 3).
Location of recurrent versus first thrombosis
Sixty-two percent of the recurrences were DVTs, 31% were PEs, 5% had DVT and PE, and 1% of 
recurrences were in a different location (upper extremity, portal vein, intestines or sinus) (table 4). 
Recurrences occurred more than expected at the same location as the first event (table 4). Patients 
Table 3. Risk factors for recurrent venous thrombosis.
*adjusted for age and sex when applicable.








(CI95) excl cancer 
and lifelong 
treatment
Men vs women 2.3 (1.9-2.7) 2.2 (1.9-2.6) 2.5 (2.1-3.0) 2.4 (2.0-2.9)
Men vs women without hormones 3.0 (2.4-3.7) 2.8 (2.2-3.6) 3.6 (2.7-4.6) 3.5 (2.7-4.5)
Age (per year) 1.01 (1.01-1.02) 1.00 (1.00-1.01) 1.00 (1.00-1.01) 1.00 (1.00-1.01)
Age categories
Age 18-30 1 (ref) 1 (ref) 1 (ref) 1(ref)
Age 30-40 0.9 (0.6-1.2) 0.8 (0.6-1.1) 0.9 (0.6-1.3) 0.7 (0.5-1.1)
Age 40-50 1.1 (0.8-1.5) 0.9 (0.7-1.3) 1.1 (0.8-1.6) 0.9 (0.6-1.2)
Age 50-60 1.2 (0.9-1.6) 0.9 (0.6-1.2) 1.3 (0.9-1.7) 0.9 (0.6-1.2)
Age 60-70 1.5 (1.1-2.0) 1.0 (0.8-1.4) 1.5 (1.1-2.1) 1.0 (0.7-1.4)
Idiopathic 1st VTE 2.0 (1.7-2.3) 1.4 (1.2-1.7) 2.2 (1.9-2.6) 1.6 (1.3-1.9)
- Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster or hormone use 
(oral contraceptives and hormone replacement therapy), and pregnancy within three months before the 
event, and without active malignancies or puerperium.
- Women without hormones were those without pregnancy, puerperium, oral contraceptive use and use of 
hormone replacement therapy.
*Adjustments were made for age and sex whenever applicable
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Figure 3. Cumulative risk of recurrence for different subgroups and different durations of treatment 
when follow-up started at time of first venous thrombosis.
- Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster or 
hormone use (oral contraceptives and hormone replacement therapy), and pregnancy within three 
months before the event, and without active malignancies or puerperium.
- Provoked venous thrombosis was defined as thrombosis due to surgery, plaster of minor injuries.
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with DVT were 1.5-fold (95%CI 1.1-1.9) more likely to have a DVT as second event than patients 
with a pulmonary embolism. Patients with a first PE were 1.9 fold (95%CI 1.4-2.8) more likely to 
get a recurrent PE than those with a first DVT or with a DVT and PE. 
In patients who had a first DVT in their left leg, the side of the recurrent DVT appeared to 
be equally distributed whereas in patients who had a first DVT in their right leg, the chance 
of a recurrent event in the right leg was slightly higher (60%) than a recurrent event in the 
left leg (table 5).
Anticoagulation therapy for the initial event
For this analysis, a total of 575 patients with a diagnosis of malignancy were excluded as these 
patients often have treatment for prolonged periods of time or for life. Of the 4156 patients 
without malignancy, duration of anticoagulation therapy for the initial event was obtained 
for 4053 (98%) patients. Numbers of patients for the different subgroups and durations of 
anticoagulation therapy are shown in table 6. Most patients (43%) received 4-6 months of 
anticoagulation treatment after the first venous thrombosis. Patients with an idiopathic 
first venous thrombosis were slightly more likely to have received more than 6 months of 
anticoagulant therapy than those with a provoked first venous thrombosis (33% vs. 28%) 
whereas patient with a clear provoking factor were slightly more likely to have received 
less than 4 months of treatment than those with a first idiopathic venous thrombosis (28% 
vs. 23%). Figure 3 shows the cumulative incidence of recurrence over time of all patients 
without malignancies for four different duration periods of anticoagulation therapy. This 
figure shows that most recurrences occurred during the first 2.5 years after the first event 
Table 4. Location first versus recurrent thrombosis, observed versus expected.
1st event
Recurrence
DVT PE DVT+PE Other Total
DVT 319 (267) 71 (99) 23 (58) 4 (0) 424
PE 44 (99) 105 (37) 4 (21) 1 (0) 157
DVT + PE 51 (58) 29 (21) 9 (13) 3 (0) 92
Total 414 (424) 205 (157) 36 (92) 8 (0) 673
N observed (N expected)




Left 79 (50%, CI95 42%-57%) 78 (49%, CI95 42%-57%) 2 (1%)
Right 54 (40%, CI95 32%-48%) 81 (60%, CI95 50%-66%) 0
Both 1 0 0
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among those with 1-3 months of anticoagulation therapy. When patients were split into 
idiopathic and provoked first venous thrombosis the difference remained after 2.5 years. 
Discussion
In this large follow-up study of 4731 patients with a first venous thrombosis followed for a 
total follow-up time of 24 124 person-years we found 683 certain recurrent events for an 
incidence rate of 27.9 per 1000 person-years and a cumulative incidence of 3 percent after 
one year. We found male sex to be a risk factor for recurrence with a 2.2-fold increased risk 
(95%CI; 1.9-2.6). An idiopathic first thrombosis was associated with a 1.4-fold increased risk 
(95%CI; 1.2-1.7) which was most pronounced in men. Increasing age was not associated with 
risk of a recurrent event. When we studied the different durations of anticoagulation therapy 
we found that most recurrences occurred in patients with less than 3 months of treatment. 
To establish the true incidence of recurrence we performed a sensitivity analysis, varying 
various aspects of the analysis, which led to a range of thrombosis recurrent rates of 
27.9-37.0 per 1000 person-years. We found an incidence of 27.9 per 1000 person-years 
when only certain recurrences were taken into account and an incidence of 37.0 per 1000 
person-years when both certain and uncertain recurrences were taken into account. 
When follow-up was started after discontinuation of treatment the range of thrombosis 
recurrence rates was 30.6-38.4 per 1000 person-years. The range of incidences of recurrent 
thrombosis we report is similar but more precise than recurrent incidences previously 
reported7,14,21,33,36,38,159. Additional to small study size, different incidence rates found in the 
literature may be explained by different definitions of duration of follow-up (starting at 
time of thrombosis or discontinuation of treatment). Both methods of defining duration 
of follow-up are justifiable, but they lead to results that should be interpreted differently 
and cannot be compared with each other. Furthermore, previous studies generally did 
not take uncertainty of recurrent events into account. In our study we showed incidences 
of recurrence both starting follow-up after the date of thrombosis and after the date of 
discontinuation of treatment. To start duration of follow-up at date of first venous 
Table 6. Number of patients per duration of anticoagulation therapy
Group of patients Total N
1-3 months oac 
N (%)
4-6 months oac 
N (%)
7-12 months oac 
N (%)
>12 months oac 
N (%)
All without malignancy 4053 1082 (27) 1756 (43) 795 (20) 420 (10)
Idiopathic 1279 297 (23) 549 (43) 288 (23) 145 (11)
Provoked 2774 785 (28) 1207 (44) 507 (18) 275 (10)
- Idiopathic thrombosis was defined as venous thrombosis without surgery, trauma, plaster or hormone use 
(oral contraceptives and hormone replacement therapy), and pregnancy within three months before the 
event, and without active malignancies or puerperium.
- Provoked venous thrombosis was defined as thrombosis due to surgery, plaster of minor injuries.
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thrombosis has the advantage that recurrences during anticoagulation treatment are 
taken into account (n=42). We chose to show the main results of only those with a certain 
recurrence, as these are most likely to truly have had a recurrent event. However, we also 
present a result where uncertain diagnoses were counted as recurrence, and one in which 
we imputed the recurrence status of patients with an uncertain recurrence. 
Recurrent events occurred more than expected at the same site as the first thrombosis, 
i.e. patients with a PE as first event were more likely to have a PE as recurrent event, and 
patients with a first DVT had more DVT as recurrence. This may be explained by damage 
to the veins at the location of the first thrombosis or by a higher awareness of thrombotic 
symptoms at the location of the first event. However, when a patient had had a first venous 
thrombosis of the left leg with a recurrence in the leg, the side of recurrence location was 
random. When the first event occurred in the right leg patients were only slightly more 
likely to have a recurrent event in the right leg. These results suggest that most recurrences 
are not due to vascular damage or residual thrombosis after the first venous thrombosis, or 
that most first DVTs are bilateral. 
We attempted to study the association between duration of treatment and the occurrence 
of recurrent venous thrombosis. Those with a treatment duration approaching 6 months 
appeared to have the lowest incidence of recurrence.  However, as this is an observational 
study we do not know the indications for the different durations of treatment. To avoid some 
of the confounding by indication for the duration of treatment we stratified the analysis for 
those with a first idiopathic and provoked venous thrombosis (figure 3b and 3c) and still 
observed the highest risk of recurrence for those with 1-3 months of therapy. It should be 
noted that we have no information on the occurrence of major haemorrhage and therefore 
cannot balance thrombosis prevention versus bleeding risk. 
In this study we found that a first idiopathic venous thrombosis is mainly a risk factor for 
recurrence in men and not in women. For women more removable provoked risk factors are 
known and therefore they are at lower risk of recurrence than men. These risk factors are not 
present in idiopathic patients. Since men with an idiopathic thrombosis were at higher risk of 
recurrence than women with an idiopathic first event the intrinsic risk of thrombosis for men 
appears to be higher than for women. Most previous studies did not stratify by sex in the analysis 
of idiopathic versus provoked first venous thrombosis and the risk of recurrence36,157,158,161. 
Increasing age did not increase the risk of a recurrent event after adjustment for sex. Similar 
results were obtained from previous studies, including our own.30,36,127  
A limitation of this study is that it was based in a clinical setting. We did not perform CUS 
for all patients after the first event to better evaluate a subsequent recurrence. However, we 
tracked all possible recurrences and had access to three sources of information to decide 
on the likelihood of a true recurrence. The sensitivity analysis showed little difference 
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between the minimum and maximum recurrence rate possible (27.9-37.0) per 1000 person-
years when follow-up started after thrombosis and 30.6-38.4 per 1000 person-years when 
follow-up started after discontinuation of treatment) as described in table 1. However, our 
study with the recurrence definition based on clinical experience gives the optimal estimate 
of true effects in clinical practice. A second limitation is that we included patients with 
a first venous thrombosis who were younger than 70 years of age. Therefore, our results 
are not generalizable to patients with a first venous thrombosis above the age of 70. A 
third limitation is that for 23% of patients limited follow-up was available. Part of these 
patients were lost to follow-up due to death. However, from some of them we still knew 
their recurrence status up to death through registries of the causes of death and information 
from the anticoagulation clinics. So, finally we did not know the recurrence status of 8% of 
patients who died, which at most would have led to a slight underestimation of the incidence 
of recurrent thrombosis. The majority of patients were lost to follow-up due to reasons that 
are unlikely to be related to the recurrence risk (non-availability of contact details). 
In conclusion, in this large study in 4731 patients with a first venous thrombosis we found 
an overall recurrence rate between three and four percent per year. The recurrence rate 
was highest during the first year after the first event (i.e. 54 per 1000 person-years) and 
decreased until it became stable at 25 per 1000 person-years at 4 years after the first venous 
thrombosis. Age did not affect the risk of a recurrent event. An idiopathic first thrombosis 
is a risk factor for recurrence only in men, and men had an overall higher risk of recurrence 
than women. For duration of treatment, sex, type of first event (idiopathic or provoked) and 
location of first event (DVT or PE) may need to be taken into account. Clinical trials are 
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Summary
Tall people have an increased risk of a first venous thrombosis. Sedentary lifestyle has been 
shown to act synergistically with body height, especially in long-haul flights. The aim of 
this study was to estimate the effect of height on the risk of a first and recurrent venous 
thrombosis and the additional effect of a mobile or immobile lifestyle in the MEGA case-
control and MEGA follow-up study. Patients with a first venous thrombosis and controls 
subjects were included between 1999 and 2004. Patients were followed for recurrence for 
an average time of 5 years. Self reported height at time of first venous thrombosis was used. 
The effect of height was estimated in 5 centimeter (cm) categories. Odds ratios and hazard 
ratios per increase of 5 cm were calculated. For both men and women a height of 165-170 cm 
was used as the reference category. In 4464 patients who reported their height we found an 
increased risk of a first and recurrent event with height. For men a more than 3-fold increased 
risk was found for those taller than 200 cm for both first and recurrent venous thrombosis. 
For women a 2-fold increased risk was found for those taller than 180 cm for both first and 
recurrent venous thrombosis. For both men and women an additional effect was observed 
for sedentary lifestyle. In conclusion, both tall men and women have an increased risk of 
first and recurrent venous thrombosis, especially in combination with a sedentary lifestyle.  
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Introduction
Tall people have an increased risk of a first venous thrombosis166–169. Body height affects 
venous pressure dynamics170,171, so taller people may have more stasis in the legs which 
could explain the increased risk. As men are taller than women most previous studies were 
restricted to men or only found an increased risk for men166,168. 
Prolonged seated immobility such as during work or long haul flights has been found to be a 
risk factor for a first venous thrombosis15,16,172. Prolonged seating induces compression of the 
poplitial vein and reduces blood flow from the lower leg. This effect will most likely be stronger 
in tall people who may be seated in a more cramped position leading to more compression of 
their poplitial vein than in people of average height. The combination of prolonged seating and 
being particularly tall was indeed found to increase the risk of thrombosis substantially during 
long haul flights15,16. The same was found for short people, where we hypothesized that their 
feet may not reach the floor in standard seats15,16. It is not well known to what extent prolonged 
immobility during daily life affects the risk of venous thrombosis in tall or short people. 
The risk of a recurrent venous thrombotic event is generally high, but low in those with 
transient risk factors. As height is a non-modifiable risk factor, it could well be that height 
also affects the risk of a recurrent event, particularly in combination with prolonged seating. 
Men have a higher risk of recurrent venous thrombosis than women, and we hypothesized 
that this could be explained by their generally greater height. 
The aim of this study was to investigate the risk of a first and a recurrent venous thrombosis 
in relation to height in men and women separately, as well as the effect of prolonged 
seated immobility in combination with body height. We studied this in a large unselected 
population of nearly 5000 patients with a first VT, of whom nearly 700 developed a 
recurrence, and 5000 control subjects.
Methods
Study population
The multiple environmental and genetic assessment (MEGA) study of risk factors for 
venous thrombosis is a large population based case-control study that included 4956 
cases with a first venous thrombosis and 6297 control subjects between March 1999 and 
September 2004. Cases were included at six anticoagulation clinics, which monitor virtually 
all outpatient treatment with vitamin K antagonists; control subjects were either partners of 
the cases (n=3297) or recruited with random digit dialing (n=3000)7,14. 
All participants of the MEGA study filled in an extensive questionnaire on risk factors for 
venous thrombosis. Body height was reported by 4464 (90%) cases and 5803 (92%) controls. 
The definition of immobility during the day was based on a combination of two questions: 1) 
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‘How do you spend most of your day?’, on which possible answers were: standing, walking, 
sitting or lying down, and 2) ‘how do you classify your daily activities regarding physical 
activity’, on which an answer could be chosen out of four categories from light to heavy. The 
answers walking and standing and the two heavy categories of physical activity during the 
day were classified as mobile and all others as not mobile. If the two questions contradicted 
each other (23%) we used the answer to the question about daily physical activity as we 
considered this question more specific for prolonged seated immobility. If participants filled 
in just one of the two questions, only that question was taken into account. The question: 
‘How do you spend most of your day’ was filled in by 3117 (30%) participants, as this question 
was present in only part of the questionnaires. In total 7414 (72%) participants filled in the 
question about their daily activity. When both questions were combined information on 
physical activity was present for 8458 (82%) participants.
Subsequently a follow-up study was performed for the 4731 cases who participated in the 
MEGA case-control study who also agreed to participate in the follow-up study, with the 
aim to establish incidence rates of and risk factors for a recurrent event. Questionnaires 
about recurrent events were sent to all patients known to be alive. In addition, we checked 
the records of all patients at the anticoagulation clinics to find all possible recurrent 
events. Recurrences were confirmed with discharge letters using a decision rule which was 
described before173. A total of 631 patients developed a certain recurrence while 184 subjects 
with uncertain recurrence were censored at time of possible recurrence. Body height as 
reported at time of first venous thrombosis and the association with prolonged immobility 
during daily life were studied as risk factors for recurrence. During follow-up 4264 (90%) 
patients had information about their body height at baseline and 3999 (85%) patients had 
information about physical activity at baseline.
Statistical Methods
Height was divided in categories of five centimeters starting from 155 centimeters up to 200 
centimeters. All participants shorter than 155 centimeters were grouped, and formed the 
lowest height category. All subjects taller than 200 centimeters formed the highest height 
category. The category of 165-170cm was used as the reference category as this category 
contained a substantial number of both men and women. 
For determining the association between height and first venous thrombosis, odds ratios 
for the different height categories were calculated as estimates of the incidence rate ratio 
(relative risk). All odds ratios were adjusted for age to take the matching into account. For 
determining the association between height and a recurrent event, incidence rates were 
calculated per height category (number of recurrences per height category per number of 
person-years per category). Hazard ratios for recurrence per height category compared 
with those of average height (165-170cm) were calculated. Overall risks of height for a first 
venous thrombosis in these data have been published earlier so here we do not repeat the 
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overall analysis but describe the results for first venous thrombosis for men and women 
separately167. For recurrent venous thrombosis, incidence rates and HRs were calculated 
overall and for men and women separately. 
We used 10 cm categories of height to study the combination of height and immobility during 
daily life. For these analyses we used a height of 160-170 cm as reference category. These analyses 
were done for both first and recurrent venous thrombosis and for men and women separately.
Results
For the case-control set up, a total of 4464 patients and 5803 controls reported their body 
height and were therefore included; 45.9% of patients and 46.2% of controls were men. 
Median age of the patients was 54.9 (5th-95th percentile 31.2-68.4) for men and 45.8 (5th-95th 
percentile 24.0-67.8) for women. Median age of the control subjects was 48.4 (5th-95th 
percentile 26.7-67.1) for men and 48.0 (5th-95th percentile 25.0-66.4) for women. Among the 
4365 patients who reported body height and participated in the follow-up study, 648 recurrent 
events were identified during follow-up. The mean duration of follow-up was 5 years. The 
overall recurrence rate among these patients was 28.5 (95CI 26.4-30.8) per 1000 person-years. 
First venous thrombosis
For both men and women an increasing risk of a first venous thrombosis with higher body 
height was found, up to a 3.8-fold increased risk (95CI 1.5-9.8) for the tallest men (>201 cm) 
and a 1.5-fold increased risk (95CI 0.7-3.4) for the tallest women (>185 cm) compared to 
subjects with a height of 165-170 cm (table 1). For men an increased risk was also found 
for the shortest participants (<155 cm) compared with subjects with a height of 165-170cm, 
although numbers were small here (OR 3.7: CI95 0.6-24.0).  
Seated immobility was associated with a 1.2-fold (95CI 1.1-1.4) increase in risk of first venous 
thrombosis for men and a 1.4-fold (95CI 1.2-1.6) increase in risk for women. When seated 
immobility during daily life was analyzed jointly with body height we found the highest risk 
in the tallest men (200-tallest) who were not mobile most of the day (OR 4.7 CI95 1.1-20.2) 
compared with men with a height of 165-170cm who were mobile during the day. This 
synergistic effect of height and immobility was only present in the tallest category (table 2). 
For women in all categories of body height a slightly increased risk of a first venous 
thrombosis was seen when these women were mainly seated during the day. The largest risk 
was found for women of 181-190cm who were not mobile (HR 3.1 CI95 1.6-6.1) compared 
with mobile women of 161-170cm (table 2).
Recurrent venous thrombosis
For recurrent venous thrombosis we also observed a gradual increase in risk with body 
height (table 3a), which attenuated somewhat after adjustment for age and sex. When we 
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stratified on sex we found an increase in risk for both tall men and women. For men of 
>200cm a HR of 3.7 (95CI 1.4-10.0) for recurrence was found compared with male subjects 
with a height of 165-170cm; for women of 186-190cm we found a HR of 3.0 (95CI 0.9-9.4) 
compared with female subjects with a height of 165-170cm (table 3B and C). Short women 
also had an increased incidence of recurrence: a 1.7-fold (95CI 0.9-3.2) increased risk for 
the shortest women with a height of 165-170cm as the reference. Overall, the same trends in 
Table 1. Body height as risk factor for a first venous thrombosis.
1st Venous thrombosis Men (N = 4729) Women (N = 5538)
Height (cm) N Cases N Controls ORadj (95% CI)* N Cases N Controls ORadj (95% CI)*
Smallest-155 3 2 3.7 (0.6-24.0) 79 113 0.9 (0.7-1.2)
156-160 5 9 0.7 (0.2-2.7) 237 370 0.9 (0.7-1.0)
161-165 39 42 1.3 (0.8-2.2) 478 700 0.9 (0.8-1.0)
166-170 136 208 1(ref) 740 956 1 (ref)
171-175 307 453 1.1 (0.9-1.5) 478 549 1.1 (0.9-1.3)
176-180 541 681 1.4 (1.1-1.8) 322 353 1.1 (0.9-1.4)
181-185 453 614 1.5 (1.1-1.9) 67 71 1.1 (0.8-1.6)
186-190 357 423 1.9 (1.4-2.5) 14 11 1.5 (0.7-3.4)
191-195 134 174 1.9 (1.4-2.7)
196-200 64 65 2.9 (1.9-4.4)
201- Tallest 10 9 3.8 (1.5-9.8)
cm=centimeters, N=number, OR=Odds ration, 95% CI=95% confidence interval, ORadj=adjusted odds ratio.
*Odds ratios were adjusted for age. 
Table 2. body height and seated immobility in daily life in relation to risk of first venous thrombosis
1st Venous thrombosis Men (N = 4558) Women (N = 4614)
Height (cm) Mobile Cases (N) Controls (N) ORadj* Cases (N) Controls (N) ORadj*
Smallest-160 Yes 1 4 0.3 (0.0-2.7) 91 114 0.9 (0.6-1.2)
Smallest-160 No 5 5 1.7 (0.4-7.6) 163 254 1.2 (0.9-1.7)
161-170 Yes 54 70 1 373 382 1
161-170 No 70 111 1.3 (0.7-2.1) 658 952 1.2 (0.9-1.4)
171-180 Yes 237 302 1.2 (0.8-1.9) 214 221 1.1 (0.8-1.4)
171-180 No 386 620 1.3 (0.9-2.0) 489 536 1.5 (1.2-1.8)
181-190 Yes 240 251 1.9 (1.3-3.0) 19 21 1.6 (0.7-3.9)
181-190# No 446 647 1.7 (1.1-2.6) 54 52 3.1 (1.6-6.1)
191-200 Yes 63 57 4.1 (2.2-7.5)
191-200 No 117 162 2.1 (1.3-3.3)
201-tallest Yes 3 2 1.9 (0.1-3.8)
201-tallest No 6 6 4.7 (1.1-20.2)
Cm=centimeters, N=number
*Odds ratio adjusted for age
# for women this category is 180-tallest
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Table 3. Body height as a risk factor for a recurrent venous thrombosis.
A: Overall
Recurrent venous thrombosis N = 4365
Height (cm) N Total N rec IR# (95% CI) HR (95% CI) HRadj (95% CI)*
smallest-155 74 11 33.9 (17.9-59.0) 1.5 (0.8-2.9) 1.6 (0.9-3.1)
156-160 225 15 11.9 (6.9-19.2) 0.6 (0.3-0.9) 0.6 (0.3-1.0)
161-165 487 43 16.3 (11.9-21.7) 0.7 (0.5-1.1) 0.8 (0.5-1.1)
166-170 826 99 21.8 (17.8-26.4) 1 (ref) 1 (ref)
171-175 763 97 23.9 (19.5-29.1) 1.1 (0.8-1.4) 0.9 (0.7-1.3)
176-180 835 142 32.9 (27.8-38.7) 1.5 (1.2-1.9) 1.1 (0.8-1.5)
181-185 493 91 37.7 (30.5-46.1) 1.7 (1.3-2.9) 1.2 (0.8-1.6)
186-190 362 90 49.1 (49.7-60.1) 2.2 (1.7-3.0) 1.5 (1.0-2.0)
191-195 129 23 33.4 (21.7-49.4) 1.5 (1.0-2.4) 1.0 (0.6-1.7)
196-200 61 15 53.0 (30.8-85.5) 2.4 (1.4-4.1) 1.6 (0.9-2.9)
201-205 9 5 111.1 (40.7-246.3) 3.2 (1.2-8.6) 3.6 (1.4-9.0)
B: men
Recurrent venous thrombosis N = 1949
Height (cm) N Total N rec IR# (95% CI) HR (95% CI) HRadj (95% CI)*
smallest-155 2 0 - - -
156-160 4 0 - - -
161-165 32 6 41.9 (17.0-87.3) 1.2 (0.5-3.0) 1.2 (0.5-2.9)
166-170 122 20 35.1 (22.0-53.2) 1 (ref) 1 (ref)
171-175 296 49 16.6 (12.4-21.7) 1.0 (0.6-1.6) 1.0 (0.6-1.7)
176-180 519 105 39.4 (32.4-47.4) 1.1 (0.7-1.8) 1.2 (0.7-1.9)
181-185 427 86 42.3 (34.0-51.9) 1.2 (0.7-2.0) 1.3 (0.8-2.1)
186-190 350 87 48.8 (39.3-59.9) 1.4 (0.9-2.3) 1.5 (0.9-2.4)
191-195 127 23 34.0 (22.1-50.2) 1.0 (0.5-1.8) 1.1 (0.6-1.9)
196-200 61 15 53.0 (30.8-85.5) 1.5 (0.8-2.9) 1.7 (0.8-3.3)
201-tallest 9 5 111.1 (40.7-240.6) 3.2 (1.2-8.6) 3.7 (1.4-10.0)
C: women
Recurrent venous thrombosis N = 2315
Height (cm) N Total N rec IR# (95% CI) HR (95% CI) HRadj(95% CI)
*
smallest-155 72 11 34.8 (18.3-60.5) 1.7 (0.9-3.3) 1.7 (0.9-3.2)
156-160 221 15 12.1 (7.0-19.5) 0.6 (0.4-1.1) 0.6 (0.3-1.0)
161-165 455 37 14.8 (10.6-20.2) 0.7 (0.5-1.1) 0.7 (0.5-1.1)
166-170 704 79 19.6 (15.6-24.4) 1 (ref) 1 (ref)
171-175 467 48 18.4 (13.7-24.2) 0.9 (0.6-1.3) 0.9 (0.7-1.3)
176-180 316 37 22.4 (16.0-30.5) 1.1 (0.8-1.7) 1.2 (0.8-1.8)
181-185 66 5 13.2 (4.8-29.3) 0.7 (0.3-1.6) 0.7 (0.3-1.8)
186-tallest 14 3 58.8 (15.0-160.1) 2.9 (0.9-9.1) 3.0 (0.9-9.4)
Cm=centimeters, N=number, rec=recurrences, IR=incidence rate, HR=Hazard ratio, 95% CI=95% 
confidence interval, HRadj=adjusted Hazard ratio.
*adjusted for age and sex in table a and age in table b and c, # per 1000 person-years
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risk of recurrence related to body height were seen in men and women (figure 1). However, 
the recurrence rate for women was lower for almost all body heights. 
Seated immobility at time of first venous thrombosis was associated with a 1.1-fold (95CI 
0.9-1.4) increased risk of recurrence in men and a 1.5-fold (95CI 1.1-2.0) increase in risk 
in women. When seated immobility was analyzed jointly with body height we saw a slight 
synergistic effect in the overall analysis (table 4A). However, when we stratified on sex this 
was attenuated and the additional effects were mainly seen in women (table 4B). For men 
we only saw an additional effect in the tallest group (>200cm) compared with those with a 
height of 161-170cm. 
Table 4A. Body height and mobility in daily life and risk of recurrent venous thrombosis.    
Recurrent venous thrombosis N=3544
Height (cm) Mobile N total N rec HR (95% CI) HRadj*
Smallest-160 Yes 89 7 0.6 (0.3-1.4) 0.6 (0.3-1.5)
Smallest-160 No 154 16 1.2 (0.7-2.1) 1.0 (0.6-1.9)
161-170 Yes 403 47 1 1
161-170 No 691 73 1.1 (0.7-1.5) 1.2 (0.8-1.7)
171-180 Yes 440 59 1.2 (0.8-1.7) 0.9 (0.6-1.4)
171-180 No 848 124 1.5 (1.1-2.1) 1.3 (0.9-1.9)
181-190 Yes 255 55 2.2 (1.5-3.2) 1.4 (0.9-2.2)
181-190 No 484 105 2.2 (1.6-3.2) 1.5 (1.0-2.2)
191-200 Yes 60 14 2.3 (1.3-4.2) 1.4 (0.7-2.7)
191-200 No 112 23 2.1 (1.3-3.5) 1.3 (0.8-2.2)
201-tallest Yes 3 1 3.5 (0.5-25.5) 2.2 (0.3-16.3)
201-tallest No 5 3 6.4 (2.0-20.5) 5.1 (1.8-14.6)
Cm=centimeters, N=number, HR=Hazard ratio, 95% CI=95% confidence interval, HRadj=adjusted Hazard 
ratio, *adjusted for age and sex































Figure 1. Incidence of recurrence per body height for men and women separately.
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Discussion
In this study body height was positively associated with the risk for both first and recurrent 
venous thrombosis, both in men and women. The effect was more pronounced in men, 
probably because they are on average taller. Prolonged seated immobility further increased 
the risk of a first venous thrombosis for men in the highest height category and for women 
in all categories. For recurrent venous thrombosis a similar pattern was observed. We 
also observed an increased risk of venous thrombosis for small people (<155 cm). For the 
shortest people an additional effect of seated immobility on the risk was found as well.  
Previous studies have shown an increased risk of a first venous thrombosis with increasing 
body height166–168 However, these studies have been performed in men only166,168 or used large 
categories of body height167 like quartiles, for which reasons an increase in risk in women 
has not been described before. The Dutch population is one of the tallest populations in the 
world, which allowed adequate numbers of tall men and women in the study. Our results on 
the combined effect of height with immobility during daily life are in line with risks found 
before for tall and short people during long haul flights.174 
To our knowledge no previous studies on the effect of body height on recurrent venous 
thrombosis have been performed. For recurrent venous thrombosis we also found a weak 
synergistic effect of body height and immobility for women. For men this synergy was 
only seen for the tallest men. For tall subjects we found a 3- to 4- fold increase in risk of 
recurrence, which are among the largest HRs found in thrombosis recurrence research. 
This study in a large group of patients is the first to show that tall women are at increased risk 
of venous thrombosis and that body height is a risk factor for recurrent venous thrombosis. 
The explanation for an increased risk for tall men and women probably lies in their long legs 
where stasis is more present due to a higher resting venous pressure.6 Although generally a 
dose-response relation appears to be present with increasing height and increasing risk, there 
seems to be a threshold (<155cm) below which the risk of (recurrent) venous thrombosis 
increases in short people. An explanation may be that these individuals in some seats cannot 
plant their feet on the floor, which leads to compression of the popliteal vein and more stasis. 
Body height cannot fully explain the overall higher risk of recurrent venous thrombosis in men 
compared to women for two reasons. Firstly, for men and women with the same body height the 
incidence of recurrence was still 2-fold higher in men than in women (figure 2). Secondly, when 
we analyzed sex as a risk factor for recurrent venous thrombosis and adjusted the estimate for 
body height the effect of sex diminished only slightly, from 2.2 to 1.8. So even after adjustment 
for body height an approximately 2-fold increase in risk for recurrence in men remains. 
A limitation of our study is that both body height and mobility were self-reported. 
However, with respect to body height misclassification would most likely be minor and 
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random and equally present in cases and controls, which would at most have attenuated 
the results. Being mobile during the day has not been questioned in great detail in our 
questionnaires. The small additional increase in risk we observed for seated immobility 
may well be larger when mobility is assessed in more detail. Only 30% of the participants 
answered the question on how they spent most of the day. This did most likely not affect 
our results because we considered the question about physical activity as the most accurate. 
Another potential limitation is that we assessed body height while leg length may be more 
informative.175 As body height already showed an increase in risk the effect of leg length is 
expected to be even stronger.  
In conclusion, in this population based study in 4464 patients with a first thrombosis of 
whom 631 had a recurrent event, we found an increased risk for both first and recurrent 
venous thrombosis with increasing body height for both men and women. The effect was 
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The aim of this thesis was to identify new risk factors for first and recurrent venous 
thrombosis of both the upper and lower extremity, and assess the incidence of recurrence 
and mortality after a first venous thrombosis. An overview was provided of the current 
literature on risk factors and treatment for a first venous thrombosis of the upper extremity 
(chapter 2). We investigated the association between levels of coagulation factors, blood 
group and a first venous thrombosis of the upper extremity (chapter 3), and studied risk 
factors for a recurrent event in patients with a first venous thrombosis of the upper extremity 
(chapter 4). Furthermore, we studied the association between venous thrombosis and 
long-term mortality (chapter 5). In this study we found that patients with thrombosis died 
more of chronic obstructive pulmonary disease (COPD) than expected from population 
figures. COPD was found to be a risk factor for a first venous thrombosis in chapter 6. We 
studied the incidence of recurrent venous thrombosis, as well as sex, age and an idiopathic 
first venous thrombosis as risk factors for recurrence (chapter 7). Body height was studied 
as a risk factor for both first and recurrent venous thrombosis in combination with 
mobility (chapter 8). In this summary chapter results are elaborated on and methodological 
considerations, clinical relevance and suggestions for further research are described.
Main findings
In this thesis, results of both the MEGA follow-up study and the MEGA case-control study 
are presented. The MEGA study is a large case-control study, in which over 5000 patients 
were included with a first venous thrombosis and over 5000 controls. Subjects were included 
between March 1999 and September 2004. Patients were included at six anticoagulation 
clinics in the Netherlands and controls were either partners of patients or were randomly 
recruited by random digit dialling. All subjects filled in an extensive questionnaire about their 
history and on potential risk factors for thrombosis. Up to June 2002 blood samples were 
collected from participants. From June 2002 until September 2004 DNA samples were taken 
with buccal swabs. In 2006 a pilot for a follow-up of the MEGA study was performed in 
all patients with a first venous thrombosis of the upper extremity. The actual collection of 
follow-up data of all patients included in the MEGA study was carried out between June 2008 
and June 2009. The aim of the MEGA follow-up study was to assess the incidence of recurrent 
venous thrombosis, to identify new risk factors for a recurrent venous thrombosis, and to 
study the association between venous and arterial thrombosis and their common risk factors.
A pilot study for the MEGA follow-up study was performed in all 226 patients with a 
venous thrombosis of the upper extremity. In this study risk factors for a recurrence after 
a first venous thrombosis of the upper extremity and differences in risk factors for a first 
upper extremity venous thrombosis and for subsequent recurrence were found. Women 
had an increased risk of recurrence after a first venous thrombosis of the upper extremity 
compared with men. A thrombosis in a different vein than the subclavian vein, high BMI, 
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patients with a first venous thrombosis of the arm. From chapter 2 we learned that levels of 
coagulation factors and blood group had not been previously studied in literature as risk 
factors for venous thrombosis of the arm. We found in our study that high levels of von 
Willebrand Factor, Factor VIII, and fibrinogen increased the risk of an upper extremity 
venous thrombosis. Patients with blood group non-O, a genetic cause of high levels of vWF 
and FVIII had an increased risk as well. Elevated levels of other coagulation factors did 
not seem to increase the risk of thrombosis of the upper extremity. In chapter 5 we report 
that venous thrombosis was associated with an increased mortality up to eight years after 
the thrombotic event. This period of eight years is much longer than described in previous 
studies. The risk of death was highest in patients with cancer, but also persistently elevated in 
those without. It was less pronounced in those who had comorbidities at the time of venous 
thrombosis. In this study we also found that patients with venous thrombosis had a 4-fold 
increased risk to die of chronic obstructive pulmonary disease (COPD). Subsequently, 
since we assumed COPD to precede venous thrombosis, we studied COPD as a risk factor 
for a first venous thrombosis in the MEGA case-control study, reported in chapter 6. COPD 
was indeed found to be associated with a 3-fold increased risk of a first venous thrombosis. 
This risk mainly concerned pulmonary embolism and was most pronounced when COPD 
was severe. In chapter 7 we described the design and first results from the MEGA follow-up 
study. In the MEGA follow-up study we found that the incidence of recurrence lies between 
27.9 and 37.0 per 1000 person-years. This range is similar to that reported in the literature. 
Men had a higher risk of recurrence than women. The increased risk of recurrence in 
patients with a first idiopathic venous thrombosis seemed almost restricted to men. In 
chapter 8 we studied the effect of body height on the risk of a first and recurrent venous 
thrombosis. Previous studies had only studied first venous thrombosis and reported an 
increased risk in tall men but not in women. We found an increased risk for both tall and 
short men and women for a first and recurrent venous thrombosis. For women these risks 
were slightly higher when these women were not active for a large part of the day.
Methodological considerations
Survival bias
The MEGA case-control study could have been affected by survival bias. Survival bias 
occurs when the exposure is related to survival, and only surviving patients are included in 
etiologic studies. The mean time between venous thrombosis and inclusion in the MEGA 
study was 1 month. This time gap was due to the way patients were included, i.e. via the 
anticoagulation clinics. These monitor outpatient treatment, so patients diagnosed with 
venous thrombosis, to be registered at an anticoagulation clinic, need to have survived the 
acute phase of the thrombotic event. This selection of survivors will only have biased the 
estimates of risk factors for first thrombosis, when these factors were related to mortality 
as well. For instance, COPD is related to both mortality and venous thrombosis. In this 
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the anticoagulation clinic than patients with only venous thrombosis. This would lead to 
an underestimation of the true effect. Since acute mortality in venous thrombosis is small, 
we do not expect major effects of this bias, except possibly in patients with malignancies.
Strength of risk factors for recurrence
Only a few risk factors are known for a recurrent venous thrombosis and they differ 
considerably in nature and strength from those for a first venous thrombosis. Part of these 
differences can be explained because provoking risk factors, such as oral contraceptives, are 
removed after the first event or because of prophylactic therapy during periods of increased 
risk such as in case of surgery or pregnancy after the first event. However, not all risk factors 
are transient or sufficient to warrant prophylaxis, such as malignancy, body height, and 
genetic risk factors. Furthermore, some risk factors for a first venous thrombosis do not 
predict recurrence, such as age, and some risk factors selectively affect recurrence, as male 
sex, as we have shown in chapter 7. When risk factors affect both first and second venous 
thrombosis the effect on recurrence appears invariably lower than that on first events 
(e.g. 5 versus 1.3-fold increase for FVL and 7 versus 1.5-fold increase for malignancies). 
These differences in relative risk can be explained by index event bias or by scale effects, i.e., 
differences in absolute risks for first and recurrent venous thrombosis. 
Index event bias
Recurrence research can be affected by a form of selection bias called index event bias. This 
bias is problematic when etiologic rather than prognostic questions are asked. Due to the 
selection of cases with a first event, risk factors are differently associated with other risk 
factors than they are in the general population. For example, one may develop a disease due 
to either risk factor A or X. In the general population A and X are not associated with each 
other (figure 1). However, in a group of patients with the disease risk factors A and X will 
be negatively associated as those with risk factor A are less likely to have X because they 
developed the disease because of A and vice versa. When for recurrence research patients 
with a first event are selected, these negative relations exist in this selected population. In 
theory, when one would study the effect of FVL on recurrence in patients with a first venous 
thrombosis the effect will be underestimated because in the selected cohort patients will be 
less likely have other risk factors for thrombosis, compared with the general population. 
Due to the selection of cases with a first venous thrombosis this association can lead to 
biased estimates (figure 1). Sometimes risk factors interact with each other, i.e., the joint 
effect is larger than expected based on the separate effects. When this is the case (and the 
interaction is supra-multiplicative among patients) among patients the relations between 
risk factor X and A will be positive and will overestimate the risk of recurrence. Venous 
thrombosis is a multi-causal disease for which many risk factors interact negatively and 
positively, and the strengths of these interactions differ among risk factors. Thereby many 
risk factors and relations between them are unknown. Therefore, it is not possible to predict 
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This bias is only a problem when the research question is etiologic or causal. In practice, 
most recurrence research will be focused on the search for factors that predict the risk of 
a recurrent event in patients with a first venous thrombosis, to identify those who would 
benefit most from anticoagulant prophylaxis. However, if targeted interventions on a single 
risk factor would be possible, e.g., an intervention that would only affect factor V Leiden, 
the effect of index event bias would be highly relevant.
Differences in absolute risks
As shown in the table the absolute risk (incidence) of a recurrent venous thrombosis is 
much higher than of a first event (1 per 1000 versus 30 per 1000 per year). It is relevant to 
note that these incidences can only be contrasted numerically, for they refer to different 
populations (e.g., everyone versus those who had a first thrombosis). Individuals who are 
‘invulnerable’ to thrombosis will be in the denominator of risk estimates of a first event, but 
not of a second event. If there is a difference in the vulnerability of developing the disease 
in question, the absolute risk for recurrence will be higher in numerical terms than that of 
a first event. The effect of a risk factor can be expressed as an incidence rate difference (risk 
difference) or an incidence rate ratio (relative risk). The risk difference is calculated as the 
absolute difference of two incidence rates, i.e., if a risk factor increases the incidence of first 
Figure 1. Directed Acyclic Graph of index event bias. Due to selection of a collider (DVT1) associations 
between the risk factors arise that are not causal.
Table
Strength RR
1st event 2nd event
Absolute risk Risk difference Absolute risk Risk difference
Baseline 1 1 per 1000 30 per 1000
Weak 2 2 per 1000 1 per 1000 60 per 1000 30 per 1000
Moderate 5 5 per 1000 4 per 1000 150 per 1000 120 per 1000
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thrombosis from 1 per 1000 person-years to 7 per 1000 person-years, with a risk difference 
of 6 per 1000 person-years. The relative risk is calculated as the ratio of the incidence rates 
of those with and those without the risk factor. In the example, the relative risk is 7. The 
difference in the baseline incidence (in the absence of the risk factor of interest) of first 
and recurrent events implies that the risk difference and relative risk for first and recurrent 
event cannot be parallel, i.e., if a factor has the same risk difference for first and recurrent 
events the relative risk will be largest for first events. This is shown in the hypothetical table, 
where absolute risks for both a first and recurrent venous thrombosis are shown and the 
increase in these absolute risks (risk difference) is calculated for constant relative risks of 
1, 2, 5 and 10. The absolute risk increases from 1 per 31.5 per year (3% per year) to 1 per 
3 (30% per year) for a relative risk of 10 for recurrent venous thrombosis. In other words, 
when the relative risk is constant. In practice this would mean that for a risk factor with a 
10-fold increase in risk for recurrent thrombosis, over 85% of patients with a first venous 
thrombosis and that risk factor would experience a recurrent event within 5 years. 
When we look at the risk differences that are actually observed, these are often larger for 
recurrent than first thrombosis. So, on an absolute scale, even if relative risks appear smaller, 
risk factors are often stronger for recurrence than for first events. For example for factor V 
Leiden, relative risk estimates are 5 for first events and 1.4 for recurrence. This would lead to 
risk differences of 4 per 1000 (5/1000-1/1000) for first events, and 12 per 1000 for recurrent 
events (42/1000 – 30/1000). In other words, on an absolute scale the effect of FVL is not 
smaller for recurrent than first events, but larger.
Clinical relevance
Upper extremity venous thrombosis
Our study on risk factors for recurrence after venous thrombosis of the upper extremity, was 
the first performed. We showed in chapter 4 that in current practice removal of risk factors, 
like CVCs, prevents recurrence in these patients. Upper extremity venous thrombosis was 
strongly related with the presence of malignancies and central venous catheters and was 
therefore strongly related with death as well. Due to this high mortality among patients 
with a first venous thrombosis of the upper extremity few patients experienced recurrent 
events, but the incidence found was as high or higher as for DVT of the leg. Recurrence 
after venous thrombosis of the upper extremity was related to BMI, location of the first 
thrombosis and being a woman. Future studies for prevention of recurrence in patients with 
upper extremity venous thrombosis are most relevant in those patients without catheters 
and malignancies. For patients with a primary or effort thrombosis of the upper extremity, 
weight loss and less strenuous exercise with the arms could prevent recurrent events. 
However, we found that 36% of all recurrences after a venous thrombosis of the upper 
extremity do not occur in the upper extremities. For these patients the origin might be 
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Mortality
In chapter 5 we describe an increased risk of death up to eight years after venous 
thrombosis. This risk was most pronounced in patients with cancer, followed by those with 
an idiopathic first thrombosis when they were compared to patients with a provoked first 
thrombosis without malignancy. The resulting decrease in median life expectancy was five 
years. The clinical implication of this study could be to check or monitor these specific 
‘healthy’ venous thrombosis patients more extensively for other diseases to prevent early 
death. Candidates for these comorbidities are the additional risks found for several causes 
of death in chapter 5. Arterial thrombosis has been found in several studies to be related 
with venous thrombosis. Some studies even suggest venous thrombosis as a risk factor for 
arterial thrombosis. Possible pathways between these diseases could be atherosclerosis 
and an inflammatory state or the presence of common risk factors for arterial and venous 
thrombosis, such as obesity and smoking. Especially the common risk factors can be 
targeted in clinical practice. 
New risk factors for recurrence
In chapter 8 we found that body height increased the risk of recurrent venous thrombosis. 
This knowledge provides better insight in the mechanism behind a venous thrombosis. 
Tall people have taller legs in which stasis can occur more easily. Stasis is one of the 
three components Virchow described as causes for venous thrombosis. Body height may 
be good tools for prediction as body height is a fixed factor. This makes body height a 
perfect candidate for prediction as most other risk factors change over time. However, with 
fixed factors only a sort of baseline risk of recurrence can be predicted, while the final 
precipitation of an event must depend on newly acquired factors.
Future studies
Difference in risk for men and women
Several studies including ours found differences in risk of recurrence for men and women. 
In chapter 7 we found a 2-fold increased risk for men compared with women for a recurrent 
venous thrombosis, which is consistent with the literature on this subject. However, in chapter 4 
we found an increased risk for women compared to men for patients with a recurrent event 
after a first venous thrombosis of the upper extremity. This difference for upper extremity can 
be explained by the mortality rates found in chapter 4. In this chapter we showed an increased 
risk of death for all patients; however, this excess risk disappeared for men when patients 
with malignancy were excluded. The risk remained increased for women. Most patients with 
malignancy in this study were men. Death due to malignancy is a large competing risk for 
recurrent venous thrombosis in patients with venous thrombosis of the upper extremity. Most 
patients with malignancy die within a year and are therefore no longer at risk for recurrence. 
As this was mainly present in men only women remain at risk for recurrence and therefore a 
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have a two-fold higher risk of recurrence than women after a venous thrombosis of the leg is 
still not understood. Future studies into the origin of this difference may give more insight in 
new risk factors and the etiology behind venous thrombosis. 
Prediction models
Future studies need to be more focused on prediction of recurrence. When the chance of 
a recurrence can be predicted with some accuracy, recurrence itself and mortality due to 
bleeding and recurrent events could be largely avoided by targeted prophylaxis. At this 
moment the focus of most prediction models is to predict recurrent events in patients with 
a first idiopathic thrombosis. However, with this method a large proportion of patients is 
ignored. Only one third of thrombotic events are idiopathic and 10 percent of patients with a 
provoked first venous thrombosis experience a recurrent event within 5 years. This indicates 
that for a large group of patients removing the known provoking factor is not sufficient to 
prevent recurrence. Therefore, in future studies the prognosis after provoked thrombosis 
should be taken into account and possibly contrasted with idiopathic thrombosis to find 
specific new risk factors for both first and recurrent venous thrombosis. Future prediction 
models should be time-dependent, for it may matter whether recurrence is predicted 
shortly after the first event, or after a longer period. The first moment to predict future risk 
is immediately after the event, but the best moment may be at the time of discontinuation 
of anticoagulant treatment, which varies between patients. In the studies currently in the 
literature most parameters are known at time of thrombosis but not at time of discontinuation 
of treatment. However, the risk profile is likely to change in the time directly following a first 
thrombosis, e.g. with respect to in oral contraceptive use or smoking habits. 
Additional to changing risk profiles, prediction of recurrence is difficult because many 
patients develop a recurrent event due to different risk factors than present at their first 
event. This can be shown by the theory of ‘causal pies’ (figure 2). Every person has different 
combinations of risk factors that may cause thrombosis. Only when all parts of a pie are 
present a thrombosis will occur. However, these pies differ between patients, and patients 
will have several pies that are partly or almost full, and many of the pieces are unknown. 
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Predictions would be made on the first completed causal pie a patient had, which we in 
most cases do not know fully. However, the pie that will cause a recurrent event can in 
theory contain completely different risk factors than the pie that caused the first event. 
Therefore, it is difficult to predict which pie will be next to become full for each person. To 
a large extent, prediction will therefore depend on causes that are part of many causal pies 
(persistent ones) or that complete many pies (newly acquired ones).
Conclusions
In this thesis we identified several new risk factors for both first and recurrent venous 
thrombosis. These factors are useful for prediction models and may improve individualised 
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In dit proefschrift worden resultaten van de MEGA en MEGA follow-up studie besproken. 
In deze onderzoeken zijn nieuwe risicofactoren gevonden voor eerste en recidief veneuze 
trombose. In hoofdstuk 2 wordt de literatuur met betrekking tot veneuze trombose van de 
arm besproken. In hoofdstuk 3 is onderzoek gedaan naar stollingsfactoren en bloedgroep 
als risicofactoren voor een veneuze trombose van de arm. Hierbij werd gevonden dat 
verhoogde concentraties van factor VIII, Van Willebrand factor, fibrinogeen en bloedgroep 
niet-O het risico op een trombosearm verhogen. Deze factoren komen overeen met factoren 
die het risico op een trombose been verhogen. Er zijn echter een aantal factoren beschreven 
die het risico op een trombosebeen verhogen, waarvoor wij geen relatie vonden met het 
risico op een trombosearm. In hoofdstuk vier werd onderzoek gedaan naar risicofactoren 
voor een recidief trombose bij patiënten met een eerste trombose van de arm. Hier werd 
gevonden dat vrouw zijn, een hoog BMI, maligniteiten en een trombose in een andere 
vene dan de subclavia een verhoogd risico geven op een tweede trombose. In hoofdstuk 
vijf wordt de mortaliteit op de lange termijn na een veneuze trombose beschreven. In deze 
studie werd gevonden dat patiënten met een veneuze trombose tot acht jaar na de trombose 
een verhoogde kans op overlijden hebben ten opzichte van de bevolking. Dit risico was 
het sterkst in patiënten die ten tijde van trombose geen bekende comorbiditeiten hadden, 
behalve patiënten met kanker, die verreweg het hoogste risico op overlijden hadden. In 
deze studie werd ook gevonden dat patiënten met trombose een vier keer verhoogd risico 
hebben om te overlijden aan COPD. In hoofdstuk 6 werd onderzocht of COPD ook een 
risicofactor is voor het krijgen van een eerste veneuze trombose. Hierbij werd gevonden 
dat COPD voornamelijk een risicofactor is voor longembolieën en in mindere mate voor 
trombose van het been. Het risico voor een longembolie neemt daarbij ook nog toe met de 
ernst van de COPD. COPD zou hiermee een risicofactor kunnen zijn voor het ontstaan van 
een trombus in de long. In het MEGA vervolgonderzoek vonden we een incidentie tussen 
de 28 en 37 per 1000 persoonsjaren voor een recidief veneuze trombose. Deze range komt 
overeen met de bestaande literatuur. Daarnaast werd gevonden dat mannen een hoger risico 
op een recidief veneuze trombose hebben dan vrouwen. Een idiopathische eerste trombose 
verhoogde ook het risico op een recidief veneuze trombose maar voornamelijk in mannen. 
Eerdere studies beschreven lengte als risicofactor voor trombose voornamelijk in mannen. 
In dit proefschrift werd de relatie tussen lengte en eerste en recidief trombose onderzocht 
in zowel mannen als vrouwen. Voor zowel eerste als recidief trombose verhoogde lang zijn 
(meer dan 1.85m voor vrouwen en meer dan 2.00m voor mannen) het risico. Ook voor 








Promoveren doe je niet alleen. Dit boekje was er dus ook zeker niet geweest zonder de hulp 
en steun van vele personen.
Allereerst wil ik alle deelnemers aan de MEGA studie bedanken en vooral iedereen die 
bereid was om meer dan 5 jaar na het patiënt-controle onderzoek nog een keer mee te doen 
met de follow-up. Zonder hen was dit proefschrift er niet geweest.
Daarnaast alle dames van het datamanagement in het bijzonder Inge en Ingeborg die me 
alles geleerd hebben over het maken van databases en goede vragenlijsten. En natuurlijk 
Anne, zonder jouw hulp waren nooit al die vragenlijsten op tijd terug gekomen. 
Natuurlijk wil ik ook al mijn andere collega’s op de afdeling klinische epidemiologie 
bedanken voor alle gezelligheid en speciaal al mijn kamergenootjes, Kirsten, JJ, Irene, 
Renée, Sara, Dinanda, Marieke en Melissa.
Lieve pap en mam, jullie ook bedankt voor alle steun en interesse in mijn onderzoek zonder 
jullie was ik nooit zover gekomen. Pap ik vind het een hele eer dat je tijdens de promotie 
naast me staat. 
Skatje! Zonder jou was het laatste stukje van m’n promotie een stuk minder leuk geweest! 
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